Selected Non-Hodgkin's Lymphoma abstracts from the American Society of Hematology (ASH) 2008 convention in San Francisco http://ash.confex.com/ash/2008/webprogram/start.html List compiled by Greg Dafoe

See the new 2013 ASH abstracts

Non-Hodgkin's Lymphoma Cyberfamily Home

 Table of contents

1. Alternative Donor Transplantation Poster
2. Biologic Therapies for NHL (Excluding Pre-clinical Models
3. Clinical Care - Transplantation Regimen Toxicities and Engraftment
4. Clinical Results - Allogeneic Matched Related Donor Transplantation 
5. Clinical Transplantation – Acute and Chronic GVHD, Infectious Complications, and Immune Reconstitution
6. Experimental Transplantation - GVHD and GVL
7. Lymphoma: Chemotherapy and Clinical Trials
8. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents
9. Non-Hodgkin’s Lymphoma - Biology, Excluding Therapy
10. Clinical Transplantation - Transplantation Regimen Toxicities and Engraftment 1
11. Clinical Transplantation: Acute GVHD Prevention and Risk Assessment
12. Alternative Donor Transplantation
13. Biologic Therapies for NHL (Excluding Pre-clinical Models)
14. Clinical Care - Recurrence, Secondary Neoplasia, and Late Complications after Transplantation
15. Clinical Care - Transplantation Regimen Toxicities and Engraftment
16. Clinical Results - Allogeneic Matched Related Donor Transplantation
17. Clinical Results - Autologous Transplantation
18. Clinical Transplantation – Acute and Chronic GVHD, Infectious Complications, and Immune Reconstitution
19. Experimental Transplantation - Basic Biology, Immune Function, and Engraftment
20. Experimental Transplantation - GVHD and GVL
21. Lymphoma: Chemotherapy and Clinical Trials Poster II
22. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents Poster II
23. Non-Hodgkin’s Lymphoma - Biology, Excluding Therapy Poster II
24. New and Emerging Biologic Therapies of NHL
25. Targeted Therapies and New Agents in Lymphoma
26. Clinical Results - Allogeneic Matched Related Donor Transplantation I
27. Mantle Cell Lymphoma, Follicular Lymphoma, Tumor Microenvironment
28. Clinical Results - Allogeneic Matched Related Donor Transplantation II
29. Diffuse Large B-cell Lymphoma: Biology and Prognosis
30. Clinical Studies in Lymphoma
31. DLBCL and Other NHL: Novel Therapeutic Targets and Approaches
32. Low Grade B-cell Lymphoma: Biology
33. Alternative Donor Transplantation Poster III
34. Biologic Therapies for NHL (Excluding Pre-clinical Models) Poster III
35. Clinical Results - Allogeneic Matched Related Donor Transplantation Poster III
36. Clinical Results - Autologous Transplantation Poster III
37. Experimental Transplantation - GVHD and GVL Poster III
38. Lymphoma: Chemotherapy and Clinical Trials Poster III
39. Non-Hodgkin’s Lymphoma - Biology, Excluding Therapy Poster III
40. Autologous Transplantation: Lymphoma
41. Clinical Transplantation - Transplantation Regimen Toxicities and Engraftment 2
42. Diffuse Large B-cell Lymphoma: Molecular Biology
43. Incorporation of Rituximab into Clinical Management of NHL
44. Preclinical Studies in NHL: Novel Antibodies and Immunotherapeutic Approaches

Alternative donor transplantation I

965 One Antigen HLA-Mismatched Related and 8/8 Allele Matched Unrelated Donors Are Associated with Similar Survival after Hematopoietic Cell Transplantation for Acute Leukemia

966 Comparable Results of HLA-Mismatched Vs HLA-Matched Unrelated Donors for Allogeneic Stem Cell Transplantation Using Pre-Transplant ATG

967 Clinical and Cost Outcomes of Double Umbilical Cord Blood Versus Bone Marrow and Peripheral Blood Unrelated Hematopoietic Stem Cell Transplants

968 Decreased Relapse Rates without Excessive Transplant Related Mortality Following Cord Blood Transplantation (CBT): A Matched Cohort Analysis Comparing Myeloablative Cord, Matched Unrelated, and Mismatched Unrelated Donor Transplants

969 Unrelated Transplants for Poor Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Comparative Analysis Based on the Hematopoietic Progenitor Source

970 Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era

971 Unrelated Bone Marrow Transplantation for Children with Chronic Myeloid Leukemia (CML): A Report from the Japan Marrow Donor Program (JMDP)

972 Comparative Outcome of Myeloablative and Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia

973 Results of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Advanced Chronic Myeloid Leukemia (CML) Patients (pts) Who Failed Tyrosine Kinase Inhibitors (TKIs) after Developing BCR-ABL Kinase Domain (KD) Mutations

974 Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients with Peripheral T-Cell Lymphoma

975 Salvage Therapy with Allogeneic Stem Cell Transplantation Results in Better Outcome for Patients with Relapsed/Refractory Follicular Lymphoma Compared to Those with Transformed Non-Hodgkin Lymphoma: A Population-Based Comparative Study

976 Treatment of AML in First Remission (CR1) with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Unrelated Donors (UD)

977 Risks and Benefits of Unrelated Donor Peripheral Blood Progenitor Cells (PBPC) in Children and Adolescents with Acute Leukemia

978 Upfront Allogeneic Stem Cell Transplantation for Remission Induction in High-Risk Acute Myeloid Leukemia Patients within the Randomized Multi-Center Trial AML2003

979 Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients (pts) with Advanced Chronic Myeloid Leukemia (CML) Post Imatinib Failure

Biologic Therapies for NHL (Excluding Pre-clinical Models

1000 A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma

1001 Elderly Patients with Mantle Cell Lymphoma (MCL) – Efficacy and Feasibility of Prolonged Immunochemotherapy with Rituximab, Cytarabine and Fludarabine Added to CHOP and Followed by Rituximab Maintenance Treatment. A Prospective Study by the Finnish Lymphoma Group

1002 A Phase I/II Study of IPH1101 (BrHPP), Specific Agonist of Vγ9Vδ2 T Lymphocytes, in Combination with Rituximab Re-Treatment in Patients with Follicular Lymphoma. Interim Phase I Data

1003 FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402:  Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R]

1004 Durable Responses in Patients Treated with Galiximab (Anti‑CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial

1005 Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL)

1006 Multiple Complete Responses in a Phase 1 Dose-Escalation Study of the Antibody-Drug Conjugate SGN-35 in Patients with Relapsed or Refractory CD30-Positive Lymphomas

1007 Phase I Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, in Relapsed Patients (Pts) with Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL): Updated Results

1008 CNTO 328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in Castleman’s Disease:  Preliminary Results of a Phase I Study

1009 A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease

1010 Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM)

1011 Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience

1012 Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients

1013 Final Results of a Phase II Danish Trial Testing Low Dose Total Body Irradiation Following Six Bi-Weekly RCHOP-14 Plus 2 Extra Rituximab in Elderly High risk Patients with Aggressive CD20+ Diffuse Large B-Cell Lymphoma (DLBCL)

1014 The Rituximab Treament for Relapsed Follicular Lymphomas Changes the Duration of Subsequent Responses. the Analysis on Behalf of CLS

Clinical Care - Transplantation Regimen Toxicities and Engraftment

1115 The Effect of Increasing CD34+ Cell Doses on Time to Engraftment after Autotransplantation for Hematologic Malignancies

1116 Comparison of Two Mycophenolate Mofetil Dosing Regimens Following Hematopoietic Cell Transplantation (HCT)

1117 Clinical Outcomes and Pharmacokinetics of Targeted Intravenous Busulfan in Children Receiving Stem Cell Transplantation for Thalassemia

1118 Optimizing the CD34+ Cell Dose for Allogeneic Transplantation

1119 The Hematopoietic Cell Transplantation Comorbidity Index: No Effect on Outcome of Reduced-Intensity Allografts

1120 Febrile Reactions Occurring with Second Cycle of High Dose Melphalan and Stem Cell Transplantation in Patients with AL Amyloidosis:  A “Melphalan Recall” Reaction

1121 Prior Treatment with Chemotherapy Associated to Gemtuzumab Ozogamicin (GO) Does Not Increase the Risk of Veno-Occlusive Disease (VOD) after Allogeneic Stem Cell Transplantation (all-SCT)

1122 Danapaloid Is Significantly Effective for the Prophylaxis of Hepatic Veno-Occlusive Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study of 85 Children with Hematological Malignancies

1123 Wireless Video-Capsule Endoscopy Is a More Sensitive Investigative Method Than Gastro-Intestinal Endoscopy and Biopsies for the Diagnosis of Acute GI-Gvhd

1124 Outcomes of Pediatric Patients with Respiratory Failure Following Hematopoietic Cell Transplant (HCT); 8 Years' Experience with High Frequency Oscillatory Ventilation (H

Clinical Results - Allogeneic Matched Related Donor Transplantation

1125 Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Versus Conventional Chemotherapy in Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Attaining Complete Remission (CR1) Post Induction Chemotherapy:  a Retrospective Case Control Study

1126 Long-Term Follow-up Results of IFM9903 and IFM9904 Trials Comparing Non Myeloablative Allotransplantation with Autologous Transplantation in High-Risk De Novo Multiple Myeloma

1128 Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival

1129 Outcome after Allogeneic Stem Cell Transplantation for Adult Acute Myeloid Leukaemia Patients Exhibiting Isolated or Associated Trisomy 8 Chromosomal Abnormality: A Survey on Behalf of the Acute Leukemia Working Party (ALWP) of the EBMT

1130 Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients

1131 Allogeneic Transplantation (HCT) for Myelodysplastic Syndrome:Recent MDACC Experience

1132 HLA-Identical Allogeneic Stem Cell Transplantation (alloSCT) for Patients with Primary Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT-LWP)

1133 Use of the Propensity Score Matching Method to Reduce Recruitment Bias in Observational Studies: Application to the Estimation of Survival Benefit of Non-Myeloablative Allogeneic Transplantation  In Patients with Multiple Myeloma Relapsing after a First Autologous Transplantation

1134 Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study

Clinical Transplantation – Acute and Chronic GVHD, Infectious Complications, and Immune Reconstitution

1145 Relationships Between Late Viral Infections and Immune Reconstitution after Hematopoietic Stem Cell Transplantation

1146 Immune Reconstitution Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: The Impact of Expanding CD28negCD8+ T-Cells on Relapse

1147 Impact of Prior Invasive Pulmonary Aspergillosis (IPA) on Outcome in Patients Receiving Reduced Intensity Conditioning (RIC) Allogeneic Haematopoietic Stem Cell Transplantation (Allo-SCT)

1148 Features of Herpesviruses (CMV, EBV, HHV6) Infections and Immune Reconstitution after Allogeneic Stem Cell Transplantation (allo-SCT) Using Alternative Donors: Comparison Between Matched Unrelated Donors (MUD) and Cord Blood (CB) as Stem Cell Source

1149 An Early CT-Diagnosis Based Treatment Strategy for Invasive Fungal Infection in Allogeneic Transplant Recipients Using Caspofungin First Line: An Effective Strategy with Low Mortality

1150 Impact of Cyclosporine a (CsA) Concentration on the Incidence of Severe Acute Graft-Versus-Host Disease (GVHD) after Allogeneic Stem Cell Transplantation (allo-SCT)

1151 Antithymocyte Globulins (ATG) as Part of the Myeloablative Conditioning (MAC) Regimen Can Reduce the Risk of Severe Graft-Vs.-Host Disease (GVHD) after Allogeneic Stem Cell Transplantation (allo-SCT) from Matched-Unrelated Donors (MUD)

1152 Incidence and Risk of Post-Herpetic Neuralgia after Varicella Zoster Virus (VZV) Infection in Hematopoietic Cell Trasnplantation (HCT) Recipients

1153 Cyclosporine dose Intensity Is a Critical Determinant of Outcome after a T Cell Depleted Reduced Intensity Allograft

1154 Use of a Potassium Channel Blocker to Inhibit Effector-Memory T Cells Isolated from Recipients of Allogeneic BMSCT

1155 Delayed Cytomegalovirus (cmv) Infection Following Hematopoietic Cell Transplantation (HCT): City of Hope (COH) Experience

1156 Phase 1 Clinical Study of Adoptive Immunotherapy with Delayed Infusion of Alloanergized Donor T Cells to Improve Immune Reconstution after Haploidentical Stem Cell Transplantation

1157 Adoptive Immunotherapy after Haploidentical Stem Cell Transplantation with T Cells Allodepleted by Photodynamic Purging

1158 A Phase I/II Trial of Bortezomib, Tacrolimus and Methotrexate for Prophylaxis of Acute Graft Versus Host Disease after HLA Mismatched Reduced Intensity Transplantation

1159 Voriconazole for Secondary Prophylaxis of Invasive Fungal Infection in Allogeneic Stem Cell Transplant Recipients: Results of the VOSIFI Study. on Behalf of the VOSIFI Study Group and the Infectious Diseases Working Party of the European Bone and Marrow Transplantation Group

1160 Clinical Significance of Serum Hepcidin-25 Levels on Early Treatment-Related Complications after Hematopoietic Stem Cell Transplantation

1161 The Pattern of KIR Ligands in Adult Patients with AML Is Associated with Various Post-Transplant Complications, Including GvHD after HLA-Matched Sibling or Unrelated Donor Transplantation

1162 Monitoring of Adenovirus Load in Stool by Real-Time PCR Permits Early Detection of Impending Invasive Infection in Patients after Allogeneic Stem Cell Transplantation

1163 Immunogenicity of the Tetravalent Protein-Conjugated Meningococcal Vaccine in Recipients of Related and Unrelated Allogeneic Hematopoietic  Cell Transplants (HCT)

1164 Initial Liver Involvement in Acute Graft-Versus-Host Disease (GVHD) Predicts a Severe Acute Gvhd and Poor Long-Term Survival

1165 SELDI-TOF-Based Proteomic Analysis of Plasma Samples as a Diagnostic Tool to Predict Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation

1166 Bone Marrow Reaction in Chronic Graft-Versus-Host Disease

1167 Development of CMV-SPECIFIC Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of NAÏVE CD8+ T Cells

1168 Selective Allodepletion by TH9402-Mediated Photosensitization Results in Early Full Donor T Cell Reconstitution in the Absence of High-Grade, Acute GvHD and Is Associated with Favorable Outcome after HLA Matched Sibling SCT for Hematologic Malignancies

1169 IgG Antibodies against Human Cytomegalovirus Late Protein UL94 in the Pathogenesis of Scleroderma-Like Skin Lesions in Chronic Graft Versus Host Disease

1170 Randomized Phase II Trial Comparing Cyclosporine (CSP) and Tacrolimus (TAC) for Methotrexate (MTX)-Free Graft-Versus-Host Disease (GVHD) Prophylaxis after Allogeneic Transplantation from a Matched Related Donor (MRD) with a Reduced-Intensity Regimen Containing Cladribine and Busulfan

1171 Human Mesenchymal Stroma Cells (hMSCs) Expanded with Human Platelets Lysate Are Safe and Effective  For the Treatment of Graft Versus Host Disease

1172 Graft Versus Host Disease (GVHD) Prophylaxis with Everolimus and Tacrolimus Is Associated with a High Incidence of Sinusoidal Obstruction Syndrome and Microangiopathy – Results of the EVTAC Trial

1173 Long-Term T Cell Immune Reconstitution in Patients Surviving 10 or More Years after Allogeneic Stem Cell Transplantation for Hematologic Malignancies

1174 Catheter Related Bloodstream Infection in Haematological Patients: A Prospective, Randomized Study Comparing Heparin-Coated with Chlorhexidine and Silver Sulfadiazine Impregnated Central Venous Catheters

1175 Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation: Impact of Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts

1176 Graft-Versus-Host Disease (Gvhd) Prophylaxis with Tacrolimus and Mycophenolate Mofetil (MMF) in 131 Matched Sibling Nonmyeloablative (NMA) Transplant Recipients: Long-Term Follow-up Confirms Extremely Low Incidence of Acute (a) Gvhd, High Incidence of Extensive Chronic (c) Gvhd and Favorable Disease Outcome

1177 T Cell Depletion with Alemtuzumab Is Associated with a High Incidence of EBV Viraemia but Low Risk of PTLD Following Allogeneic Stem Cell Transplantation

1178 Macrophage Infiltration of Skin Lesions Correlates to Prognosis of Gvhd; A Clue to Refractory Gvhd

1179 Thrombotic Microangiopathy in Patients with Allogeneic Hematopoietic Stem Cell Transplantation

1180 Autoantibody Production during Chronic Graft-Versus-Host Disease Does Not Associate with Long-Term Persistence of Host B Cells in Humans

1181 Adoptive Transfer and Consequential Selective Reconstitution of Streptamer-Selected Cytomegalovirus- Specific CD8+ T Cells Leads to Enduring Virus Clearance in Patients after Allogeneic Stem Cell Transplantation

1182 Reconstitution of CD52-Negative CD4 T Cells after Alemtuzumab-Based T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

1183 Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease

1184 Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease

Experimental Transplantation - GVHD and GVL

1245 Human Alloreactive CD4+ T Cells as Potent Effector Cells and Sole Mediators of Anti-Tumor Responses in a NOD/SCID Mouse Model for Human Acute Leukemia

1246 MHC-Matching at 5 Loci Results in Higher Levels of Engraftment of Allogeneic Cord Blood (CB) Hematopoietic Stem Cells (HSC) Following Neonatal Transplantation

1247 Characterization of Cytotoxic T Lymphocyte Clones Isolated from Bone Marrow Transplant Recipient with HLA-Cw-Mismatched Donor

1248 Blocking of IL-21 Signal Attenuates Graft-Versus-Host Disease but Not Graft-Versus-Leukemia Effect in a Mouse Model

1249 Molecular Identification of Individual T Cell Clones Specific for Graft-Versus-Leukemia Reaction

1250 Interleukin-17-Producing T Cells: A New Potential Player Mediating Graft Versus Host Pathology  In Patients Undergoing Allogeneic Stem Cell Transplantion

1251 Immunomodulatory Effects of Vitamin D: Implications for the Prevention and Treatment of Graft Versus Host Disease

1252 CD11b- Donor Dendritic Cells Enhance Donor T-Cells' Th1 Polarization and Graft Versus Leukemia Activity in Allogeneic Hematopoietic Stem Cell Transplantation

1253 Donor Single Nucleotide Polymorphism in the CCR9 Gene Affects the Incidence of Acute Skin Graft-Versus-Host Disease

1254 Methylation in the Promoter Region and Expression of FOX-P3 Correlate with Graft Versus Host Disease, Relapse and Survival after Allogeneic Stem Cell Transplantation

Lymphoma: Chemotherapy and Clinical Trials

1557 Human Herpesvirus 8 Protein K1 Interference with Fas-Mediated Apoptosis Induces Clonal Growth Which Leads to Lymphoid Hyperplasia

1558 Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG)

1559 Supportive Efficacy Analyses for the Phase 3 Study of Temsirolimus Versus Investigator's Choice Therapy for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma

1560 The Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Mantle Cell Lymphoma Previously Treated with Bortezomib: Pooled Data from Two Phase II Studies (NHL-002 and NHL-003)

1561 Farnesyltransferase Inhibitor Tipifarnib (Zarnestra) in Refractory Mantle Cell Lymphoma (MCL): A Therapeutic Target Only for Specific Patients Categorized by the 2-Gene Classifier for Predictive Response to Tipifarnib

1562 A Phase II Trial of Darinaparsin in Advanced Lymphomas: Report on Safety and Activity

1563 A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Administered on Days 1 and 15 Every 28 Days without and with Prophylactic G-CSF in Non-Hodgkin or Hodgkin Lymphoma

1564 A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in  Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium Study

1565 Phase I and Pharmacokinetic Study of Inotuzumab Ozogamicin (CMC-544) as a Single Agent in Japanese Patients with Follicular Lymphoma Pretreated with Rituximab

1566 Plitidepsin Is Active in Peripheral T-Cell Lymphoma (PTCL): A Subset Analysis from An Ongoing Multicenter Phase II Trial

1567 Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL)

1568 Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma  (Molecular Analyses Included)

1569 Pralatrexate (PDX) IS Active in Cutaneous T-Cell Lymphoma: Preliminary Results of a Multi-Center Dose-Finding Trial

1570 A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies

1571 Flavopiridol, Fludarabine and Rituximab (FFR): An Active Regimen in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma

1572 Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma

1573 Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms

1574 Weekly Treatment with a Combination of Bendamustine and Bortezomib in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma: A Single-Center Phase 1/2 Study

1575 Interim Results of the RiPAD+C Regimen Including Velcade in Front Line Therapy for Elderly Patients with Mantle Cell Lymphoma. A Phase II Prospective Study of the GOELAMS Group

1576 Tolerability and Efficacy of Bortezomib Added to CVP-R for Previously Untreated Advanced Stage Follicular Lymphoma: Interim Analysis of a Phase II Study by the NCIC Clinical Trials Group

Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents

1577 Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells

1578 Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX

1579 A Novel mTOR Kinase Inhibitor Causes Growth Inhibition, Cell Cycle Arrest, Apoptosis and Autophagic Cell Death in Mantle Cell Lymphoma Cell Lines: A Distinct Profile from Rapamycin

1580 Characterization of MDX-1401, a Human Anti-CD30 Antibody with Enhanced Effector Function, for Therapy of Malignant Lymphoma

1581 T Cell Modulation Combined with Intratumoral CpG Cures Lymphoma without the Need for Chemotherapy

1582 IL-10 Present in the B Lymphoma Microenvironment Drives Macrophages to Efficient Tumour Suppressing Cells with High Phagocytic Activity in Presence of Rituximab

1583 Preclinical Analysis of the Combined Activity of SGN-40, Anti-CD40 Monoclonal Antibody, with Rituximab in Non-Hodgkin Lymphoma

1584 A Promising Therapeutic Implication of a Novel Bcl-2 Family Inhibitor ABT-737 for Adult T-Cell Leukemia/Lymphoma

1585 Compared Antitumor Activity of GA101 and Rituximab against the Human RL Follicular Lymphoma Xenografts in SCID Beige Mice

1586 Combined Treatment with Short Synthetic Anti-Lymphoma Peptide and CpG ODN; A Therapeutic Vaccine Which cures the A20 Lymphoma in Balb/C Mice

1587 The Histone Deacetylase Inhibitor Vorinostat Induces Apoptosis in T-Cell Lymphoma Cell Lines and Synergizes with Bortezomib

1588 Radioimmunotherapy of Non-Hodgkin Lymphoma is Improved without Increasing Toxicity by Combination with Antibody immunotherapy

1589 In-Vitro Treatment with the AKT-Inhibitor GSK 690693 Induces Cell Death in Lymphoma Cell Lines and in Primary CLL Cells and Is Followed by Caspase-3 Activation and Cytochrome C Release

1590 A Novel Anti-CD20 IgG-Interferon-α2b Fusion Protein with Potent in Vitro and in Vivo Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method

1591 Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity

1592 Anti-Tumor Activity of the Aurora a Inhibitor MLN8237 in Diffuse Large B-Cell Lymphoma Preclinical Models

1593 Identification of a Diagnostic Gene Signature for SGN-40, Anti-CD40 Monoclonal Antibody, in Pre-Clinical NHL Models and the Role of FAS in SGN-40 Mediated Apoptosis

1594 Cytotoxic Activity of Histone Deacetylase Inhibitor ITF2357 on Burkitt's Lymphoma Cell Lines Is Associated to Micro-RNA Modulation and Transglutaminase 2 Restoration

1595 Inhibition of Human Lymphoma Cell Growth by the PKC-Beta Selective Inhibitor Enzastaurin (LY317615) in Combination with Multiple Therapeutic Agents

1596 Molecular Mechanism by Which Rituximab Sensitizes B-NHL Cells to TRAIL Apoptosis: Induction of RKIP and DR5 Expression Via Inhibition of NF-Kb, Snail, and YY1

Non-Hodgkin’s Lymphoma - Biology, Excluding Therapy

1763 Absolute Lymphocyte Count at the Time of Relapse Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma

1764 Rac1 GTPase Targeting Inhibits p53-Deficiency Mediated Lymphomagenesis

1765 Analysis of Cytogenetic Abnormalities and Their Prognostic Impact in a Series of 145 Mantle Cell Lymphoma Cases with An Abnormal Karyotype

1766 Proteomic Analysis of Chronic Malignant B-Cell Derived Microparticles Reveals CD148 as a Potential Antigenic Marker for Mantle Cell Lymphoma Diagnosis

1767 Targeting CDK4 in Mantle Cell Lymphoma (MCL) Cell Lines by Specific Lentiviral shRNA Mediated Knockdown Has Profound Effects on Cell Growth and Cell Cycle but Minimal Effects on Apoptosis

1768 Prognostic Value of Angiogenic Factors (Vacular Endothelial Growth Factor [VEGF] and Basic Fibroblast Growth Factor [bFGF]) and Endostatin in Patients with Non-Hodgkin Lymphoma

1769 Genome Wide Analysis of 41 Mycosis Fungoides Tumor Stage Using Array Comparative Genomic Hybridization Technology

1770 Incidence and  Clinicopathological Relevance of Gene Copy Number Abnormalities Detected by a Single Quantitative PCR Assay in Mantle Cell Lymphomas

1771 Deletions of Chromosomes 6q and 13q, and Trisomy 4 Are the Most Common Cytogenetic Abnormalities in Waldenstrom Macroglobulinemia. Preliminary Results of a Multicentric Study

1772 Low Ratio of Inter-Follicular CD8/FOXP3-Positive Regulatory T-Cells Is Associated with a favourable Overall Survival in Follicular lymphoma (FL)

1773 In Follicular Lymphoma (FL), γδt-Lymphocytes (γδT) Are Present and Expandable from Peripheral Blood and Rare in Tumour Lymph Nodes, Mostly in Peri-Follicular Areas

1774 Proteomic Analysis for the Identification of Disease Biomarkers and Therapeutic Targets in Natural Killer Cell Lymphoma

1775 Splenic Marginal Zone B-Cell Lymphoma: Clinical Clustering of Immunoglobulin Heavy Chain Repertoires

1776 Outcomes and a New Prognostic Model in Posttransplantation Lymphoproliferative Disorders (PTLD):  Intent-to-Treat (ITT) Analysis of 81 Patients in the Post-Rituximab Era

1777 Family History of Cancer and Risk of Lymphoma: Influence of IL8RB, GGH IVS7 and IL10 Polymorphisms

1778 IgG-Secreting B-Cell Lymphoplasmocytoid Leukaemia : Molecular Characterization of Igh Rearrangements

1779 CS-1 Is Expressed in Nasal Type NK/T Cell Lymphomas and Angioimmunoblastic T-Cell Lymphomas: Implications for Targeted Therapy with Elotuzumab (HuLuc63)

1780 Indolent Mantle Cell Lymphoma (MCL): A Retrospective Detailed Clinical and Morphological Analysis of 21 Patients, with Histological, Cytological, Cytogenetic, Interphase Genetic, Immunoglobulin Gene, and Gene Expression Profiling Analysis

1781 Clinical Significance of CD21 Co-Expressed with LFA-1 in Non-Hodgkin’s B-Cell Lymphoma

1782 Clinicopathologic Analysis of Primary Gastrointestinal T-Cell Lymphoma with a Special Reference to Intestinal and Gastric Type in Japan

1783 Vitamin D, Sun Exposure, and Lymphoma Risk

1784 A Critical Analysis of Prognostic Factors in Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma: A Multicenter Clinicopathologic Experience and New Prognostic Score

1785 Cutaneous Lymphocyte Antigen and TRAF-1 Are Useful in Differentiating Lymphomatoid Papulosis, Cutaneous ALCL and Systemic ALCL

1786 Loss of CIITA and MHC Class II Expression in Diffuse Large B-Cell Lymphoma Is Not Explained by Methylation of CIITA Promoters III and IV

1787 Expression of CD20 but Not EBV Is Associated with Significantly Improved Overall (OS) and Event Free Survival (EFS) in Children with Post Transplant Lymphoproliferative Disease (PTLD) Following Solid Organ Transplantation (SOT)

Clinical Transplantation - Transplantation Regimen Toxicities and Engraftment 1

49 Treatment-Related Mortality  and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG)

50 Polyoma (BK) Viruria Prior to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) from Donors Other Than Matched Siblings: A Prospective Evaluation of Hemorrhagic Cystitis (HC) Incidence

51 Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults

52 Clinical and Genetic Factors Underlying Acute Bone Mineral Density Loss by 100 Days after Blood and Marrow Transplantation: A Potential Early Regimen-Related Complication

53 Treatment-Related Mortality in Patients with AL Amyloidosis Undergoing High-Dose Melphalan and Stem Cell Transplantation: Trend Over the Past 14 Years at a Single Institution

 54 Darbepoetin-Alfa and I.V. Iron Administration after Autologous Hematopoietic Stem Cell Transplantation : A Prospective Randomized Multicenter Trial

Clinical Transplantation: Acute GVHD Prevention and Risk Assessment

55 BMT CTN 0302: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox, and Pentostatin in Combination with Corticosteroids in 180 Patients (pts) with Newly Diagnosed Acute Graft Vs. Host Disease (aGVHD)

56 Post-Transplantation High Dose Cyclophosphamide (Cy) Is Effective Single Agent for Prevention of Acute and Chronic Graft Versus Host Disease after Myeloablative HLA Matched Related and Unrelated Bone Marrow Transplantation (BMT)

57 A Randomized Prospective Multicenter Phase III Trial Comparing Standard GvHD Prophylaxis with Cyclosporine and Methotrexate with Additional Pretransplant ATG Fresenius (ATG-F) in Allogeneic Stem Cell Transplantation from Matched Unrelated Donors

 58 Donor-Recipient Mismatches in MHC Class I Chain-Related Gene a (MICA) in Unrelated Donor (UD) Transplantation

59 Impact of Highly Conserved HLA Haplotype on Acute Graft-Versus-Host Disease in Unrelated Bone Marrow Transplantation

60 Minor Histocompatibility Antigen Mismatches and Graft Versus Host and Relapse in High-Resolution HLA-Matched Allogeneic Hematopoietic Stem Cell Transplantation

Alternative Donor Transplantation

1957 Favorable Leukemia-Free Survival (LFS) for Adults and Children Undergoing Myeloablative Umbilical Cord Blood (UCB) Transplantation with Cyclophosphamide (CY), Fludarabine (FLU) and Total Body Irradiation (TBI): A Single Center Analysis of 194 Patients

1958 High Rate of Second Malignancies after Reduced Intensity Double Cord Blood Transplants in Adults

1959 Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Indolent Non-Hodgkin Lymphoma: Interim Analysis of a Phase II Study

1960 Prospective Phase II Study of Biologic Assignment One Vs Two Unit Umbilical Cord Blood Transplant (UCBT) in the Reduced-Intensity Conditioning Setting

1961 Direct Intra-Bone Cord-Blood Transplantation Overcomes the Problem of Graft Failure Even When Low Numbers of HLA-Mismatched Cord-Blood Cells Are Transplanted, Thus Leading to the Possibility of Use of This Technique in a Large Number of Patients

1962 Haploidentical Allogeneic Hematopoietic Cell Transplantation in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Interim Analysis of a Phase I/II Study

1963 Single Institute Analysis of Reduced Intensity Cord Blood Transplantation from Unrelated Donors for Adults with Advanced Lymphoid Malignancies

1964 Encoraging Results after Alternative Donor Transplantation for Myelodysplastic Syndrome

1965 Interest of Non-Myeloablative Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: A Multicenter Retrospective Study

1966 Stem Cell Transplantation in Elderly Patients with Acute Lymphoblastic Leukemia (ALL) in First Complete Remission (CR1)

1967 Unrelated Cord Blood Transplantation after Nonmyeloablative Conditioning : Single Institutional Retrospective Comparison with Bone Marrow or Peripheral Blood Stem-Cell Transplants

1968 Donor Characteristics Affecting Graft Failure and Survival after Unrelated Donor Transplantation with Reduced Intensity Conditioning Regimens (RIC) for Hematologic Malignancies

1969 Cord Blood (CB) Unit Mononuclear Cell (MNC) Dose: Effect on Transplantation Outcome and Relevance to Processing Method and CBU Selection

1970 Reduced-Intensity Unrelated Cord Blood Transplantation in Adult – a Single Center Analysis of  318 Transplants

1971 Improved Outcome for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Poor Risk Cytogenetics – Result from An Analysis on 172 Patients Receiving FLAMSA-RIC Conditioning for Allogeneic Stem Cell Transplantatioin (SCT)

1972 Double Cord Blood Cell (CBC) Hematopoietic Stem Cell Transplantation after Standard or Reduced Intensity Conditioning: Report of the SFGM-TC Registry

1973 Rapid NKG2D Reconstitution on NK Cells Possibly Plays a Major Role in the Development of Graft-Versus-Leukemia Effect in the Early Period after Unrelated Cord Blood Transplantation

1974 Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study

1975 Single Donor 4/6 Matched Banked Unrelated Cord Blood Is An Effective Graft Source for Children Undergoing Myeloablative Transplantation for Malignant and Nonmalignant Disorders: Single Center Analysis of 318 Patients

1976 Engraftment Syndrome Following Unrelated Cord Blood Transplant in Pediatric Patients

Biologic Therapies for NHL (Excluding Pre-clinical Models)

1997 Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission

1998 Safety in Patients Receiving Maintenance Rituximab for Follicular Lymphoma: Results from Phase IIIb MAXIMA Trial

1999 Alemtuzumab-CHOP for Aggressive T Cell Lymphoma. A Phase II HOVON 69 Trial

2000 Effect of Prior Rituximab on Residence Time of I131 Tositumomab Consolidation Therapy in Patients (pts) with Non Hodgkin's Lymphoma (NHL): Analysis of SWOG Clinical Trials

2001 Phase II Study of Short Course CHOP-Rituximab Followed by 90-Y Ibritumomab Tiuxetan as First-Line Treatment for Follicular Lymphoma: An Update and Extension of Preliminary Findings on Predictors of Relapse

2002 Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma

2003 Comparing Standard IPI with Revised-IPI in Patients with Diffuse Large B-Cell Lymphoma: Which Has a More Differential Potential for Predicting the Outcomes after R-CHOP Chemotherapy

2004 A Phase II Trial of Combination Bortezomib (Velcade®) and Rituximab for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)

2005 Phase I Results of Combination Gemcitabine and Bortezomib (Velcade®) for Relapsed/Refractory Nodal T-Cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL)

2006 Prognostic Value of Early 18fluorodeoxyglucose PET Scan in Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab Plus CHOP or High-Dose CHOP

2007 First-Line Treatment with Rituximab Combined with Intravenous or Oral Fludarabine for Patients with Extranodal Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

2008 A Cumulative Series from 14 Western Countries Suggests That Rituximab Significantly Changed the Dismal Natural History of Intravascular Large B-Cell Lymphoma (IVL) 

2009 Front-Line Chemo-Immunotherapy Rituximab-FC + Rituximab Maintenance in Patients with Untreated Advanced Stage Non Follicular Lymphoma (INFL): Preliminary Results of a Prospective Study of the Intergruppo Italiano Linfomi and Roche (ML18324)

2010 Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma

2011 Comparative Outcomes Following CP-R, CVP-R and CHOP-R in Patients with Waldenstrom’s Macroglobulinemia

Clinical Care - Recurrence, Secondary Neoplasia, and Late Complications after Transplantation

2130 Obesity in Survivors of Childhood Hematopoietic Stem Cell Transplantation

2131 Pre-Transplant Bone Status Evaluation in Patients Undergoing Allogeneic Stem Cell Transplantation

2132 Long-Term Immune Deficiency (ID) after Allogeneic Stem Cell Transplantation (allo-SCT) Following a Myeloablative (MA) Conditioning Regimen

2133 Longitudinal Trends in Peripheral Blood Parameters Predict Development of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia (t-MDS/AML) after Autologous Transplantation for Lymphoma

2134 Quantification by Superconducting Quantum Interference Device (SQUID) of Iron Overload after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

2135 Bone Complications Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Prospective Study

2136 Pulmonary Function in Pediatric survivors of non-Malignant Disorders after Allogeneic Hematopoietic Stem Cell Transplantation

2137 Late Pulmonary Dysfunction in Long-Term Survivors after allogeneic  Hematopoietic Stem Cell Transplantation with Intensified Conditioning Regimen Including Thiotepa, Cyclophosphamide, and Total Body Irradiation

2138 High Prevalence of Vitamin D Deficiency in Allogeneic Stem Cell Transplant Recipients

2139 The Prevalence of 25-Hydroxyvitamin D Deficiency in Post-HSCT Pediatric Patients

2140 Genomic Instability Is Frequent in Oral and Rare in Nasal Mucosal Cells of Allogeneic HCT Recipients

2141 Efficacy of Imatinib Mesylate in the Treatment of Refractory Sclerodermatous Chronic Graft-Versus-Host Disease

2142 Long Term Follow-up and Matched Pair Analysis of Adjuvant Donor Lymphocyte Transfusions Following Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-Risk AML

2143 5–azacitidine Treatment of Imminent Relapse Defined by Decreasing Donor CD34+ Progenitor Subset Chimerism in Patients with CD34+ High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) after Allogeneic Stem Cell Transplantation

2144 The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Predicts Survival and Non-Relapse Mortality in Lymphoma and Myeloma Patients Undergoing Reduced-Intensity or Non-Myeloablative Allogeneic Stem Cell Transplantations   

2145 High-Dose Therapy with Peripheral Blood Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin’s Disease: A Single-Institution 20-Year Follow-up Experience

2146 Long Term Outcomes for Patient with Diffuse Large B-Cell (DLBCL) or Hodgkin's Lymphoma (HL) following Autologous Stem Cell Transplant (ASCT) Who Are Disease Free at Five Years Post Transplant

2147 Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

2148 Isolated Extra-Medullary Relapse of Acute Leukemia after Allogeneic Stem-Cell Transplantation; Different Kinetics and Better Prognosis Than Systemic Relapse

2149 Treosulfan Compared to Total Body Irradiation-Based Preparative Regimens Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia : A Retrospective Long-Term Study

Clinical Care - Transplantation Regimen Toxicities and Engraftment

2150 Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML

2151 Cost Analysis of Mobilization and Autologous Transplantation in Patients Who Received AMD 3100 after Failing Standard Mobilization

2152 Relationship of Targeted Busulfan Exposure to Engraftment in Children Undergoing Myeloablative Matched Sibling Donor Transplantation for Sickle Cell Disease

2153 Outcomes of Allogeneic Stem Cell Transplant in Patients with Myeloid Leukemias Over 65 Years of Age. Rationale for Aggressive Therapy with Curative Intent

2154 Novel Tyrosine Kinase Inhibitor Therapy Before Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia

2155 Non-Relapse Mortality (NRM) after Autologous Stem Cell Transplant (ASCT) Is Reduced with Stringent Follow-up Post-Transplant

2156 Possible Role of Engraftment Syndrome in Myelodysplastic Syndrome after Autologous Transplants

2157 Impact of Donor/Recipient Major ABO Mismatch on Allogeneic Transplantation Outcome According to Stem Cell Source: Results from An 809-Patient Retrospective Study

2158 Monitoring of  Post-Transplant Hematopoiesis in Patients Receiving High-Dose Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) with Autograft: Lack of Detection of Remarkable Abnormalities

2159 Delayed Platelet Engraftment and Early Increased Creatinine after Stem Cell Transplant Predicts Sustained Remission in Pediatric Leukemia

2160 CD8-Depleted Donor Lymphocyte Infusions Convert Mixed into Complete Donor T-Cell Chimerism after T-Cell Depleted Allogeneic Stem Cell Transplantation

2161 An Analysis of Toxicities and Time to Engraftment Associated with Three Distinct Melphalan Treatment Schemas in Patients with Multiple Myeloma Receiving Autologous Hematopoetic Stem Cell Transplantation

2162 Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years

2163 Bronchoscopic Evaluation of Pulmonary Complications in Patients Undergoing Reduced-Intensity Versus Full-Intensity Transplants

2164 No Impact of Postremission Consolidation Chemotherapy Before Allogeneic Transplant in Patients with First Remission Acute Myeloid Leukemia with Intermediate or High Risk Cytogenetics

Clinical Results - Allogeneic Matched Related Donor Transplantation

2165 Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Patients with High-Risk Multiple Myeloma (MM): A Survey from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire

2166 Allogeneic Hematopoietic Stem-Cell Transplantation in AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: Long-Term Follow-up

2167 Higher Absolute NK Count on Day30 after HLA Identical Sibling Allogeneic Stem Cell Transplantation and a “Favorable KIR” Genotype Are Associated with Faster NK Maturation and Other Functional Differences

2168 Similar 5-Year Survival after Peripheral Blood Autotransplants (AutoPB) Versus HLA Matched Sibling Myeloablative Transplants (AlloBMT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)

2169 Hematopoietic Recovery and Overall Survival after HLA-Matched Sibling Transplants for Older Patients with Severe Aplastic Anemia (SAA)

2170 Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL)

2171 Updated Results of JALSG AML201 Study Comparing Intensified Daunorubicin with Idarubicin in Patients with De Novo Acute Myeloid Leukemia: Effect of Hematopoietic Stem Cell Transplantation

2172 Incidence of Late Failure Following Myeloablative Conditioning with BuCy2 and Matched Sibling Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

2173 Comparison of Outcome Between Refractory/Relapsed De Novo Diffuse Large B-Cell and Transformed Lymphoma Using Related and Unrelated Allogeneic Hematopoietic SCT

2174 Chimerism and Tolerance after Combined Human Kidney and Hematopoietic Cell Transplantation Using Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin

Clinical Results - Autologous Transplantation

2175 Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma

2176 BuCy Provides Equivalent Outcomes to VCyTBI as Conditioning Prior to Auto-SCT in Patients with Relapsed/Refractory NHL and Is a Valuable Option in Older (≥60 years) Patients

2177 Prognosis Value of [18f] FDG-PET Prior Versus after Autologous Stem Cells Transplantation in High Grade Non-Hodgkin’s Lymphoma

2178 The Role of FDG-PET in Hodgkin Lymphoma S/P Autologous Hematopoietic Cell Transplant (HCT) as a Predictor of Outcome

2179 Outcome of Transplant-Eligible Patients with Hodgkin Lymphoma with An Inadequate Response to Second Line Chemotherapy with Gemcitabine, Dexamethasone, Cisplatin (GDP)

2180 Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma

2181 HIV Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT) for B Cell Non Hodgkin Lymphoma (NHL)

2182 Impact on Progression Free Survival of Autologous Stem Cell transplantation after Consolidation with Alemtuzumab in Chronic Lymphocytic Leukemia

2183 15 Year Follow-up of ABMT for NHL: Surprisingly Favorable Outcome for Younger Adults

2184 Length of Stay among Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma:Predictive Factors and Prognostic Effect

2185 Long Term Molecular Remissions after Autologous Haematopoietic Stem Cell Transplant in Follicular Lymphoma

2186 Superior Survival in Non-Hodgkin Lymphoma Following Autologous Stem Cell Transplantation with Intravenous Busulfan, Cyclophosphamide, and Etoposide

2187 Red Marrow Dosimetry and Stem Cell Reinfusion in High Dose 90 Y - Ibritumomab Tiuxetan

2188 Complete Remission on 18F-FDG-PET Prior to Autologous Stem Cell Transplantation Predicts Superior Event Free Survival of Patients with Relapsed or Refractory Hodgkin Lymphoma

2189 Impact of Autologous Stem Cell Transplantation and/or Rituximab on Outcome of Patients with Relapsed Follicular Lymphoma- Retrospective Analysis of 2 Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG)

2190 Prolonged PFS after Autologous Stem Cell Transplantation in Follicular Lymphoma Patients: A Long-Term Retrospective Study

2191 High Dose Therapy and Autologous Stem Cell Transplantation Still Improves Progression Free Survival in First Relapse for DLBCL in the Rituximab Era: A Study Using Patients as Their Own Controls

2192 Fludarabine, but Not Mitoxantrone, Increases the Risk of a Poor Stem Cell Harvest and Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia (tMDS/AML) after Autologous Stem Cell Transplantation (ASCT) in Patients with Follicular Lymphoma (FL)

2193 Achievement a Negative 18-FDG/PET Status at the End of Procedure by Tailored Treatment According Pre-Transplantation Pet Status in Lymphomas Improve 5 Years-OS and EFS

2194 Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma

Clinical Transplantation – Acute and Chronic GVHD, Infectious Complications, and Immune Reconstitution

2195 Hemorrhagic Cystitis and BK Virus Infection in Children after Hematopoietic Stem Cell Transplantation

2196 IFN-γ Induced by PHA Stimulation as New Marker for Gvhd Prediction in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

2197 Reactivation of Cured Hepatitis B Virus after Allogeneic Hematopoietic Stem Cell Transplantation and Its Asociation with Liver Graft Versus Host Disease

2198 Identification of New Minor Histocompatibility Antigens (mHags) in Patients with Chronic Graft Versus Host Disease (GvH) after Allogeneic Stem Cell Transplantation by SEREX

2199 Predominant Reconstitution of B Lymphoid Precursors (Hematogones) Following Unrelated Cord Blood Stem Cell Transplantation

2200 Risk Factors and Survival Analyses of Ocular Graft-Versus-Host Disease (GVHD) in the Current Era of Allogeneic Stem Cell Transplant (SCT)

2201 The Impact of NOD2/CARD15, TLR and IL23R   Polymorphisms on the Incidence of Infectious Complications in Allo-HSCT Recipients

2202 Analysis of a New graft–versus‑host Disease (GvHD) Prophylaxis Regimen with Additional Enteric‑coated Mycophenolate Sodium (EC‑MPS) Starting 10 Days after Unrelated Allogeneic Stem Cell Transplantation

2203 Phase I Study of Transfer of CD8 Depleted Donor Leukocytes after Allogeneic Stem Cell Transplantation

2204 Reconstitution of Regulatory T Cells Involves in the Development of Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation

2205 Clinical Significance of Autoantibody Expression in Allogeneic Stem Cell Recipients

2206 The Promising Strategy of Mycophenolate Mofetil Dosing to Prevent Moderate- to Severe-Acute Graft-Versus-Host Disease

2207 Multivirus-Specific T Cell Immunotherapy to Prevent or Treat Infections of Stem Cell Transplant Recipients

2208 HHV6-Associated Limbic Encephalitis after Reduced-Intensity Umbilical Cord Blood Transplantation

2209 Association of Mannose Binding Lectin (MBL-2) Deficiency with Pulmonary Infection after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

2210 High Overall Response Rate in Calcineurin Inhibitor-Free Treatment with the mTOR Inhibitor Everolimus in Advanced Extensive Chronic GvHD after Allogeneic Stem Cell Transplantation

2211 Significantly Reduce Acute Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation by Using Cord Blood as the Third Party Cells

2212 Evidence of a Significant Contribution of Thymic Output to T Cell Reconstitution Following Full Haplotype Mismatched Stem Cell Transplant (HSCT) Leading to a Predominantly Naïve Phenotype

2213 Cytomegalovirus (CMV)-Specific CD8+ T Cells Are Associated with Control of Viral Reactivation Post-Hemopoietic Stem Cell Transplantation (HSCT) Only If Shown to Be Functionally Active

2214 Use of the Tetanus Toxoid, Reduced Dose Diphtheria and Pertussis Vaccine (Tdap) in Allogeneic Transplant (alloHCT) Recipients

2215 Clinical Outcome of Aspergillus-Specific Cytotoxic T Lymphocytes for Refractory Invasive Aspergillosis in Patients with Hematological Malignancies

2216 Sirolimus-Containing Graft-Versus-Host Disease Prophylaxis and High-Resolution HLA Typing Improves the Outcome of Mismatched Unrelated Donor  Allogeneic Hematopoietic Stem Cell Transplantation

2217 Assessment of Durability of Response in Patients with Skin Graft Versus Host Disease beyond Six Months Treatment with Extracorporeal Photopheresis: Reduction of Steroid Resistance and Evaluation of Long-Term Therapy on Survival

2218 The Effect of Donor Lymphocyte Infusion Dose on the Occurrence of Severe Life-Threatening Acute Graft-Versus-Host Disease Early after Reduced Intensity Conditioning T Cell Depleted Stem Cell Transplantation

2219 Association of Treatment with Sirolimus (SIR) and Calcineurin Inhibitor (CNI) for Prevention or Treatment of Graft-Vs-Host Disease (GVHD) with Transplant Associated Microangiopathy (TAM)

2220 Early Lymphocyte Recovery Predicts Superior Survival after Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Transplantation for Patients with Hematological Malignancies

2221 Comparison of Immune Reconstitution after Unmanipulated HLA-Mismatched/ Haploidentical Blood and Marrow Transplantation and Unmanipulated HLA-Matched Sibling Transplantation in Patients with Hematological Malignancies

2222 Universal CD137 Expression upon Activation Allows Efficient Isolation of a Broad Repertoire of Virus-Specific CD8+ and CD4+ T Cells for Adoptive Immunotherapy

2223 Improved Overall Survival in Patients Recovering with High Gamma/Delta T Cells after Allogeneic Haematopoietic Stem Cell Transplantation

2224 Reactivation of Human Herpes Virus 6 (HHV6) during Hematopoietic Stem Cell Transplantation: Risk Factor Analysis of HHV6 Encephalitis and Survival

2225 Generation of Combined CD8+ and CD4+ T Cell Lines with High Specificity for Adenovirus Hexon Epitopes for Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation

2226 Increase in Proportion of Th-17 Lymphocytes in Blood Heralds Overt Acute Graft Versus Host Disease in HSCT Patients

2227 Donor Type Impacts the Incidence of Severe Acute but Not Chronic Graft-Versus-Host Disease (GVHD) after Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation (ASCT) for Treatment of AML/MDS

2228 Plasmacytoid CD123+ Dendritic Cell Recovery Is An Independent Predictor of Survival after Unrelated Cord Blood Transplant (UCBT)

2229 Cyclosporine a and Mycophenolate Mofetil Vs Cyclosporine a and Methotrexate as Gvhd Prophylaxis in Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation from HLA-Identical Sibling Donor

2230 The Influence of Cytochrome P450 3A Gene Polymorphisms on Tacrolimus Concentrations in Hematopoetic Stem Cell Transplantation Patients

2231 Increased Type I Interferon Signaling and Inflammatory Factors Associated with T-Bet+ Cytotoxic Effectors in Chronic Graft Versus Host Disease of Oral Mucosa

2232 Rituximab Prophylaxis of EBV Reactivation after Alternative Donor Transplants Following Anti-Thymocyte Globulin-Based Conditioning Regimens

2233 Early Prediction of Acute Gvhd Based on Molecular Profiling at the Time of Engraftment after Hematopoietic Stem Cell Transplantation

2234 Rituximab Infusion Two Months after HCT Decreases Alloreactive B Cell Responses While Recipient Plasma Cells Persist

2235 A Randomized, Controlled Trial of Graft-Versus-Host Disease (GVHD) Prophylaxis Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate: Analysis of GVHD, Relapse and Survival

2236 The Distribution of KIR Gene in Chinese Population and the Effect of Donor KIR and Patient HLA Genotypes on Outcome Following Allogeneic Hematopoietic Stem Cell Transplantation

2237 The FcγRllla Polymorphism Correlates with Chronic Graft-Versus-Host Disease and Treatment Related Mortality

2238 Functional Control of CMV Reactivation Is Profoundly Influenced by CMV Serostatus after Nonmyeloablative Hematopoietic Cell Transplantation Following a TLI-ATG Preparative Regimen

2239 Re-Evaluation of Chronic Graft-Versus-Host Disease Using National Institute of Health Consensus Criteria

2240 Comparison of Cyclosporine and Methotrexate with Cyclosporine and Mycophenolate Mofetil for Gvhd Prophylaxis in Myeloablative Allogeneic Bone Marrow Transplantation

Experimental Transplantation - Basic Biology, Immune Function, and Engraftment

2317 Sensitization to Minor Histocompatibility Antigens Poses a Barrier in Transplantation and Can Be Prevented by CD154:CD40 Co-Stimulatory Blockade

2318 CD8+/TCR- Facilitating Cells Induce Generation of Regulatory T cells in Vivo: Chimeric Regulatory T Cells are Antigen-Specific and Enhance Engraftment of Allogeneic HSC in Non-Obese Diabetic (NOD) Mice

2319 Fully Functional NK Cells Promote Graft-to-Leukemia Effect, after Cord Blood Transplantation

2320 Horizontal Gene Transfer through Apoptotic Bodies Confers a Possible Mechanism of Epithelial Chimerism after Allogeneic Hematopoietic Cell Transplantation

2321 Co-Transplantation of MSC Improves the Engraftment of HSC after Auto-iBMT in Non-Human Primates

2322 Humanized Sc(Fv)2 Minibody against C-Mpl Successfully Increased Platelet Number in Monkey and Increased Engraftment of Human Umbilical Cord Blood Cells in NOD/SCID Mouse

2323 Ex-Vivo Acquisition of Central Memory Phenotype Is Critical for Tolerance Induction by Donor Anti-3rd party CD8 T Cells in Allogeneic Bone Marrow Transplantation

2324 Ex Vivo Expansion and Long-Term Hematopoietic Reconstitution Ability of Sorted CD34+CD59+ Cells from Patients with Paroxysmal Nocturnal Hemoglobinuria

2325 Interaction with Human Stromal Cells Enhances CXCR4 Expression and Engraftment of Cord Blood Lin-CD34- Cells Via Wnt Signaling

2326 Dose and Timing Limitations in the Use of Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Experimental Arthritis

2327 5-Androstene-3b,17b-Diol Administration of Mice Exposed to Total Body Irradiation Results in Rapid Reconstitution of Immature Bone Marrow Progenitor Cells and Synergizes with Thrombopoietin but Not with Granulocyte-Colony Stimulating Factor

2328 A Novel SNP-Based Method for Assessing Langerhans Cell Chimerism Following Hematopoietic Stem Cell Transplantation in Humans

2329 siRNA-Induced Transient Silencing of PTEN Expression Enhances Human Hematopoietic Cell Engraftment in NOD/SCID/γcnull Mice and Increases Gene Transduction Efficiency

2330 Control of the HSC Niche Signaling for the Efficient Long-Term Engraftment of Hematopoietic Stem Cells without Irradiation or High-Dose Chemotherapy

2331 Cyclosporine, but Not mTOR Inhibitors, Hampers the Reconstitution of Bone Marrow-Derived Tregs in Long-Term Complete Donor chimeras 

2332 Donor-Specific Tolerance Induction through Expansion of DCregs and Tregs by a Liposomal Formulation of KRN7000 (RGI-2001)

2333 Compared to Adult Peripheral Blood T Cells, Cord Blood T Cells Show Enhanced Immunological Recognition of Chronic Lymphocytic Leukemia Tumor Cells

2334 In Vivo Development of Murine NK Cells Early after Congeneic BMT: Effects of MHC Molecules, and the Administration of hIL-15

2335 The Antioxidant Inflammation Modulator, CDDO-Me Promotes Myelopoiesis in Mice

2336 Conversion to Full Donor Chimerism without Gvhd Using High-Dose DLI in Minimally Conditioned Miniature Swine Recipients of Haploidentical HCT

2337 Pharmacological Inhibition of EGFR Signaling Enhances G-CSF Induced Hematopoietic Stem Cell Mobilization

Experimental Transplantation - GVHD and GVL

2338 Graft-Versus-Host Tolerance in Dogs Following T-Cell Depleted Bone Marrow Transplantation with Absorbed ATG or CD6-Antibody

2339 UTY-Coded Minor Histocompatibility Antigens as Targets for a Graft-Versus-Host Reaction against Hematopoietic Cells in the Dog

2340 TCRbeta Gene Rearrangements for Detection and Monitoring of Minimal Residual Disease after Allogenic Stem-Cell Transplantation in Patients with Advanced Mycosis Fungoides and Sézary Syndrome

2341 Roscovitine Prevents Alloreactive T Cell Expansion and TNF-a-Mediated Proinflammatory Gene Expression and Protects against GvHD

2342 Donor T Cell Production of IL-21 Accelerates Graft-Versus-Host Disease Lethality

2343 Paradoxical Effects of Interferon-γ in Allogeneic Bone Marrow Transplant: Donor Dendritic Cells Regulate Graft-Versus-Leukemia and Graft-Versus-Host Disease Activities

2344 Large Scale Selective Ex Vivo Expansion of CD4+CD25+FOXP3+ Regulatory T Cells from Peripheral Blood

2345 Donor Bone Marrow Derived IL-17 Expressing Cells Exacerbate Chronic Graft-Versus-Host Disease in a Murine Bone Marrow Transplantation

2346 Peripheral Alloantigen Drives Early Dysfunction and Eventual Exhaustion of CTL Following Delayed Donor Leukocyte Infusions

2347 GITR Ligand on Leukemic Myeloid Dendritic Cells Suppresses Induction of Leukemia-Associated Antigen-Specific CTLs from Naïve CD8+ T Cells

Lymphoma: Chemotherapy and Clinical Trials Poster II

2585 A Prospective Multicenter Phase II Study by the Puget Sound Oncology Consortium (PSOC) of Gemcitabine (G), Carboplatin (C), Dexamethasone (D), and Rituximab (R) in Patients with Relapsed/Refractory Lymphoma

2586 Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorethamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL)

2587 Incidence, Predictors and Significance of Severe Toxicity in Patients with HIV-Associated Hodgkin Lymphoma

2589 Characteristics of Refractory and Relapsing Patients with Diffuse Large B-Cell Lymphoma

2590 Long Term Follow-up of the GELF86 French and Belgian Trials : Complete Remission after First Line Treatment with Conventional Chemotherapy in Newly Diagnosed Follicular Lymphoma Patients Correlates with Prolonged Overall Survival Compared with Partial Remission

2591 Chemotherapy Alone for Localized Non-Bulky HOODGKIN Lymphoma

2592 PET-CT Adapted Therapy after 3 Cycles of ABVD for All Stages of Hodgkin Lymphoma. Interim Analysis. Preliminary Results in 102 Patients

2593 Relapse after Autologous Stem Cell Transplant (ASCT) for Diffuse Large B Cell Lymphoma: Clinical Outcome and Prognostic Factors Affecting Long-Term Outcome

2594 BEACOPP Chemotherapy Is Able to Induce Durable Complete Remission in Poor-Prognosis Hodgkin’s Lymphoma Patients with a Positive Interim PET after 2 ABVD Cycles

2595 A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results

2596 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Studygroup Indolent Lymphomas (StiL)

2597 Hodgkin’s Lymphoma(HL) in Tunisia Results of a 5 Year  Prospective Multicenter Trial in 251 Pts

2598 A Prospectively Randomized Placebo-Controlled Trial of Epoetin-α in Patients with Advanced-Stage Hodgkin Lymphoma: Final Analysis of the GHSG HD15-EPO Trial

2599 Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months

2600 The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG)

2601 Rituximab Plus Gemcitabine, Ifosfamide, Oxaliplatin (R-GIFOX), a New Effective Cytoreductive/Mobilizing Salvage Regimen for Relapsed and Refractory Hodgkin Lymphoma

2602 Long Term Follow-up Analysis of HD9601 Trial Comparing ABVD Vs Stanford V Vs MOPPABVCAD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. A Study from the Intergruppo Italiano Linfomi (IIL)

2603 Late Relapse of Localized High-Grade Non-Hodgkin's Lymphoma: Clinical and Biological Features

2604 Duration of First Remission in Diffuse Large B-Cell Lymphoma (DLBCL) Define Groups of Patients with Different Overall Survival Which Cannot Be Entirely Distinguished by Clinical Features or IPI at Diagnosis: a Prospective Population Based Study of the Scotland and Newcastle Lymphoma Group

Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents Poster II

2605 Preclinical Rationale for the Use of the Multikinase Inhibitor Sorafenib in the Treatment of Human Lymphomas

2606 Stimulation of T Cells by Lenalidomide Involves Putative Lenalidomide Binding Proteins CD3-Epsilon-Associated Protein and GDP-Mannose Pyrophosphorylase a

2607 The Acquirement of Rituximab Resistance Is Associated with a Global Downregulation of CD54 in B-Cell Lymphoma Cells: The Potential Role of Adhesion Molecules in Rituximab Anti-Tumor Activity

2608 Prolonged Inhibition of BCR Signaling and Suppression of B Cell Lymphoma through Irreversible Inhibition of Bruton's Tyrosine Kinase

2609 Enzastaurin Displays Activity against Follicular Lymphoma Cells : Role of mTOR Pathway

2610 Synergistic and Persistent Effect of T-Cell Immunotherapy with Anti-CD19 or Anti-CD38 Chimeric Receptor on B-Cell Lymphoma in Conjunction with Rituximab

2611 The Novel Proteasome Inhibitor NPI-0052 Induces the Expression of Raf-1 Kinase Inhibitor Protein RKIP) in B-NHL Via Inhibition of the Transcription Repressor Snail : Roles of Snail and RKIP in Sensitization to TRAIL Apoptosis

2612 Direct Inhibitory Effects of Lenalidomide on the Proliferation and VEGF Production of Non-Hodgkin Lymphoma Cells Are Associated with Increased SPARC Expression

2613 Inhibition of NF-Kb Cell Signaling and Induction of the Metastasis Suppressor and Immune Surveillance Cancer Gene RKIP Expression in B-NHL by the Novel Humanized BM-Ca Anti-CD20 Monoclonal Antibody: Implication in Chemo and Immune-Sensitization

2614 PKC412, a Small Molecule Tyrosine Kinase Inhibitor, Regulates Survival and Proliferation Pathways in Waldenstrom Macroglobulinemia

2615 The Tyrosine Kinase Src Regulates Adhesion and Survival in Waldenstrom Macroglobulinemia

2616 Lenalidomide Enhances Anti-Tumor Effect of γδ T Cells against Mantle Cell Lymphoma

2617 Regulation of Histone Deacetylase in Waldenstrom Macroglobulinemia

2618 Development and Therapeutic Potential of An Anti-CD79b Antibody-Drug Conjugate, Anti-CD79b-Vc-MMAE, for the Treatment of Non-Hodgkin's Lymphoma

2619 Development of Vaccine-Based Immunotherapy for Murine Large B-Cell Lymphoma

2620 The “Side-Population” of Human Lymphoma Cells Have Increased Chemo-Resistance, Stem-Cell Like Properties and Are Potential Targets for Immunotherapy

2621 XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies

2622 Characterization and Novel Treatment for Therapy-Resistant Mantle Cell Lymphoma Isolated from Liver and Kidney

2623 Generation of CD8 T Cell-Mediated Protective Immunity against Tumor Escapees

2624 The Functional Impact of PKCß/PI3K/AKT Signalling on Translational Initiation in MCL

Non-Hodgkin’s Lymphoma - Biology, Excluding Therapy Poster II

2812 Serum Concentration of L-Kynurenine Can Determine Clinical Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP

2813 Abnormalities in Serum Free-Immunoglobulin Light Chains Show a High and Differential Frequency among WHO Subtypes of B-Cell Non-Hodgkin’s Lymphoma (NHL) and May Turn of Value for Therapeutic Monitoring: A Study of 354 Newly Diagnosed Patients

2814 Translocations Involving 8q24 in Burkitt Lymphoma and Other Malignant Lymphomas: A Historical Review of Cytogenetics in the Light of Todays Knowledge

2815 Combined FOXP3+ and PD1+ T Cell Density and Architectural Patterns Predict Overall Survival and Risk of Transformation in Uniformly Treated Patients with Follicular Lymphoma

2816 Human T-Cell Leukemia Virus Type 1 Tax Activates Caveolin-1 Gene Expression

2817 Significance of Serum Soluble IL-2R in DLBCL and FL Is Different from That in ATL

2818 Gene Expression Profiling Reveals a Crucial Role for C/EBPbeta in Proliferation Pathways of ALK+ ALCL Cell Lines

2819 Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Composite Histology Have Improved Early Outcome Compared to De Novo DLBCL When Treated with R-CHOP

2820 T-Cell Receptor Signaling Proteins, BCL10 and Phosphorylated-P65 NF-KB, Are Expressed in Peripheral T-Cell Lymphomas and Associated with Clinical Outcome

2821 Clinical Significance of Serum TARC/CCL17 in ATLL Patients: High TARC/CCL17 Level Is a Significant Unfavorable Prognostic Factor

2822 Extended Focal Imaging Reveals An Improved Gauge of Angiogenic Activity and Highlights the Role of Angiogenesis in Survival and Time to Transformation in Follicular Lymphoma

2823 EBV-Negative Post-Transplant Lymphoproliferative Disorder (PTLD): A Retrospective Case-Control Study of Clinical and Pathological Characteristics, Response to Treatment and Survival

2824 Assessment of Microrna Expression in Mantle Cell Lymphoma Using High Throughput Techniques

2825 Migratory Activity and Stromal Cell Adhesion of Mantle Cell Lymphoma Cells Can Be Diminished by Blocking of VLA-4 and CXCR4 Receptors

2826 CD74 Is a Regulator of Fas-Mediated Apoptotic Signaling

2827 Expression, Role in Transformation and Prognostic Significance of the Transcription Factor Yin Yang 1 (YY1) in Non-Hodgkin’s Lymphoma: Analyses in NHL Tissues by Experimental and Bioinformatic Approaches

2828 Validation of Mantle Cell International Prognostic Index (MIPI) in Mantle Cell Lymphoma (MCL) in a Retrospective Single Institution Series 

2829 Neuroinflammatory and Neurodegenerative Markers in Non-Hodgkin’s Lymphoma and Hematologic Malignancies with Central Nervous System Involvement

2830 Relapsed MALT Lymphomas Are Associated with a Restricted VH3-30.3 Immunoglobulin VH Gene Repertoire and Are Targeted by Aberrant Somatic Hypermutation

2831 Circulating Antibodies to ALK Inversely Correlat with Relapse Risk and Circulating Tumor Cells in Children and Adolescents with ALK-Positive Anaplastic Large Cell Lymphoma

2832 FLIPI and F2 Index – Prognostic Indices in Advanced Stage Follicular Lymphoma

2833 Central Nervous System (CNS) Relapse in Extranodal NK/T Cell Lymphoma, Nasal Type: When Do We Need CNS Prophylaxis in Patients with Extranodal NK/T Cell Lymphoma?

2834 Proportions of Bone Marrow Lymphocyte Subsets Predict Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Independent of International Prognostic Index

2835 Interest and Prognosis Value of Fluorine-18-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography ([18F] FDG-PET/CT) in Aggressive T-Cell Lymphomas

2836 Prognostic Impact of Microvessel Density in Follicular Lymphoma Patients Treated with Immunochemotherapy

New and Emerging Biologic Therapies of NHL

229 Post-Transplant Lymphoproliferative Disorder: Evaluation of Effectiveness of Reduction of Immunosuppression or Systemic Chemotherapy

230 Complete Tumor Responses in Lymphoma Patients Who Receive Autologous Cytotoxic T Lymphocytes Targeting EBV Latent Membrane Proteins

231 Yttrium-90 Radiolabeled Humanized Monoclonal Antibody to CD25 in Refractory and Relapsed Hodgkin's Lymphoma

232 Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502

233 Phase I Dose-Escalation Trial of BI 2536, a Polo-Like Kinase 1 Inhibitor, in Relapsed and Refractory Non-Hodgkin’s Lymphoma

234 A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Malignant Disease

235 Idiotype Vaccination of Untreated Indolent B-Cell Lymphoma: Durable Objective Remissions and Association of Superior Outcome with Cellular Immune Responses

236 A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma

Targeted Therapies and New Agents in Lymphoma

261 PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid Supplementation in Patients with Replapsed or Refractory Peripheral T-Cell Lymphoma

262 Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: Results of An International Study (NHL-003)

263 Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study

 264 Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma

265 VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network

266 Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study

267 Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103-104 in Patients with Relapsed NHL

268 Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Diffuse Large-B-Cell Lymphoma: Results of An International Study (NHL-003)

Clinical Results - Allogeneic Matched Related Donor Transplantation I

343 Lower Relapse Incidence and Relapse Mortality in Patients Transplanted from a Younger Sibling in HLA-Identical Stem Cell Transplantation: Does Microchimerism Matter?

344 Prognostic Factors in Patients Receiving An Allogeneic Stem Cell Transplantation for Relapsed AML. Results of the Prospective AML 295 and 01/99 Studies

345 Impact of Cytogenetics Risk on Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) from An HLA Identical Sibling for Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)

346 Non-Myeloablative Hematopoietic Stem Cell Transplantation in Older Patients with AML and MDS: Results from the Center for International Blood and Marrow Transplant Research (CIBMTR)

347 Allogeneic Stem Cell Transplantation (Allo-SCT) in Adults with Acute Myelogenous Leukemia (AML).　Final Analysis of JALSG AML97 Study

348 Similar Outcomes Using Myeloablative Versus Reduced Intensity and Non-Myeloablative Allogeneic Transplant Preparative Regimens for AML or MDS: From the Center for International Blood and Marrow Transplant Research

Mantle Cell Lymphoma, Follicular Lymphoma, Tumor Microenvironment

373 The Mir-17~92 Cluster Enhances Cell Growth and Resistance to Chemotherapy in Mantle Cell Lymphoma by Down-Regulating PTEN, PHLPP2 and BIM

374 Protein Profiling of Plasma Membranes and Lipid Rafts Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma

375 Agricultural Pesticide Use  and the T(14;18) Connection to Lymphomagenesis

376 MUM1 Expression in Follicular Lymphoma Is a Poor Prognostic Marker in Patients Treated with Immunochemotherapy (SWOG 9800/9911) but Not Chemotherapy Alone (SWOG 8809): A Southwest Oncology Group Correlative Science Study

377 Signaling Diversity in Human Lymphoma B Cells and in Tumor Infiltrating T Cells Correlates with Follicular Lymphoma Patient Clinical Outcomes

378 Monocytes Promote Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma and Are Recruited to the Tumor Microenvironment by CCL5 (RANTES)

Clinical Results - Allogeneic Matched Related Donor Transplantation II

457 Identification of Prognostic Factors Predicting the Outcome of Reduced Intensity Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma. An Analysis from the Lymphoma Working Party of the EBMT

458 Reduced Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results in An Improved Progression Free Survival When Compared to Autologous Stem Cell Transplantation. An Analysis from the Lymphoma Working Party of the EBMT

459 Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHCT) for Patients Relapsing after Autologous Stem Cell Transplantation (autoHCT) for B Cell Non-Hodgkin Lymphoma (NHL)

460 RIC Allogeneic Transplantation Improves the Overall and Progression-Free Survival of Hodgkin Lymphoma Patients Relapsing after Autologous Transplantation: A GITMO Retrospective Study Based on Time of HLA-Typing and Donor Availability

461 Donor Versus No Donor Analysis of Newly Diagnosed Myeloma Patients Included in the HOVON 50/54 Study

462 Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation during First Complete Remission Following Imatinib-Combined Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Diffuse Large B-cell Lymphoma: Biology and Prognosis

475 Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma

476 Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R:  a CALGB 50103 Correlative Science Study

477 Deletion in Chromosome 17p12 and Gains in Chromosome 9q33.3 by Array Comparative Hybridization Are Associated with R-CHOP Treatment Failure in Patients with Diffuse Large B Cell Lymphoma

478 Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP

479 Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP

480 The Pharmacogenetic Background of the Host Is An Independent Predictor of Outcome and Toxicity in Diffuse Large B Cell Lymphoma Treated with R-CHOP21

Clinical Studies in Lymphoma

577 The Impact of the Association of Vinblastine during Induction Chemotherapy and as Maintenance Treatment in Children and Adolescents with High-Risk Anaplastic Large Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group

578 Sequential Evaluation of Outcome in Enteropathy Associated T Cell Lymphoma Comparing Standard Therapeutic Approaches – Surgery or CHOP-Like Chemotherapy with a New High Dose Ifosfamide / Methotrexate and Autologous Stem Cell Transplant Regimen: A Prospective Study of Scotland and Newcastle Lymphoma Group

579 A Prospective Phase II Trial of An L-Asparaginase Containing Regimen in Patients with Refractory or Relapsing Extra Nodal NK/T-Cell Lymphoma

580 Randomized Phase II Trial on Primary Chemotherapy with High-Dose Methotrexate Alone or Associated with High-Dose Cytarabine for Patients with Primary CNS Lymphoma (IELSG #20 Trial): Tolerability, Activity and Event-Free Survival Analysis

581 RCHOP and RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : Final Results of a Phase II Study from the GELA

582 Molecular Remission after Combined Immunochemotherapy Is of Prognostic Relevance in Patients with MCL: Results of the Randomized Intergroup Trials of the European MCL Network

583 Statin Use and Prognosis in Patients with Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL)

584 The Role of Radiotherapy to Bulky Disease in the Rituximab Era: Results from Two Prospective Trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL) for Elderly Patients with DLBCL

DLBCL and Other NHL: Novel Therapeutic Targets and Approaches

601 Interleukin-21 Induces Cell Cycle Arrest and Apoptosis of Diffuse Large B-Cell Lymphomas (DLBCL) Via Activation of STAT3 and Upregulation of C-Myc

602 Antitumor Efficacy of the Purine-Scaffold Hsp90 Inhibitor PU-H71 in Diffuse Large-B Cell Lymphoma

603 Histone Deacetylase Inhibition with LBH589 Inhibits the Rapamycin Insensitive Rictor-mTOR (mTORC2) Complex and Translation Initiation Factor eIF4E Activation in Diffuse Large B-Cell Lymphoma

604 Onco-Mir-155 Targets SHIP to Regulate TNF-Dependent B-Cell Lymphoma Growth

605 The BH3-Mimetic Obatoclax (GX15-070) Posses a Dual-Mechanism of Action and Induces Both Apoptosis and Autophagy-Dependent Cell Death of B Cell Non-Hodgkin’s Lymphoma (B-NHL) Cells

606 MLN4924, a Novel Small Molecule Inhibitor of Nedd8-Activating Enzyme, Demonstrates Potent Anti-Tumor Activity in Diffuse Large B-Cell Lymphoma

607 Epigenetic Silencing of BIM Mediates Chemotherapy Resistance of Patients with Burkitt Lymphoma That Can Be Overcome by Therapeutic Reactivation of BIM in Mouse and Human Lymphoma Models

608 Gene Expression and Proteomic Profiling Predict Therapeutic Response to ABT-737 in Human and Mouse Models of Mantle Cell Lymphoma

Low Grade B-cell Lymphoma: Biology

617 Gene Expression Profiling of Post-Follicular B-Cell Lymphoma

618 Comprehensive Analysis of the Waldenström Macroglobulinemia “Cytokine Milieu” Reveals a Novel Role of Rantes Signaling in the Regulation of Immunoglobulin Production

619 TRAF3 and TNFAIP3, Two Negative Regulators of NF-Kb Signaling Pathways, Are Mutated in Waldenström’s Macroglobulinemia

620 miRNA Analysis Identifies a Unique Expression in Waldenström Macroglobulinemia B Cells and Plasma Cells

621 High Resolution Array-Based Analysis in Marginal Zone Lymphomas and Lymphoplasmacytic Lymphomas Identified Disease-Specific Patterns of Chromosome Abnormalities

622 Array-CGH Identifies Both Common and Subtype-Specific Genomic Aberrations in Marginal Zone Lymphomas

623 Immunoglobulin Gene Repertoire in Ocular Adnexa Lymphomas (OAL): Hints on the Nature of the Antigenic Stimulation

624 Mir-21 Is Over Expressed in Aggressive SMZL

Alternative Donor Transplantation Poster III

2993 Donor/Recipient Mixed Chimerism Does Not Predict Graft Failure in Children with Beta-Thalassemia Given Allogeneic Cord Blood Transplantation from An HLA-Identical Related Donor

2994 A Regimen of Treosulfan and Fludarabine Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for High-Risk Hematologic Malignancies Is Associated with Low Treatment-Related Mortality

2995 Dose Escalated Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Aggressive Non-Hodgkin Lymphoma: An Interim Analysis of a Phase I/II Study

2996 Cord Blood (CB) Extends Transplant Access to Racial and Ethnic Minorities: A Prospective Study of 309 Unrelated Searches in Patients with High-Risk Hematologic Malignancies

2997 The Comparison Between Matched Related Donor and Alternative Donor for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acquired Aplastic Anemia: KSBMT2007-02 Study

2998 Alternate Donor HCT for Fanconi Anemia (FA): Results of a Total Body Irradiation (TBI) Dose De-Escalation Study

2999 Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS

3000 Platelet Recovery Prior to Stem Cell Transplantation Predicts for Post-Transplant Outcomes in Patients with AML

3001 The Effect of the CASP8 -6526N Del Promoter Polymorphism on Outcome in T-Cell Depleted Unrelated Donor Haemopoetic Stem Cell Transplants (HSCT)

3002 Anti-Leukemia Activity of Alloreactive NK Cells in Haploidentical HSCT in Pediatric Patients: Re-Defining the Role of Activating and Inhibitory KIR

3003 Perfect Engraftment after Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Transplantation in Severe Aplastic Anemia: Phase II Prospective Multi-Center Study in Korea

3004 Contribution of HLA Incompatibility on Clinical Outcomes of CBT in Patients with MDS Including Secondary AML in Japan: Multivariate Analysis Using Competing Risk Regression Model

3005 Mismatching at HLA-DPB1 Is Not Associated with Survival in Patients with Acquired Aplastic Anemia Who Receive Unrelated Bone Marrow Transplantation

3006 Impact of Conditioning Regimen in Allogeneic Hematopoetic Stem Cell Tansplant for Children with AML beyond the First Complete Remission: Total Body Irradiation Versus Busulfan- a Pediatric Blood and Marrow Transplant Consortium (PBMTC) Study

3007 Insufficient Evidence for Association of NOD2/CARD15 or Other Inflammatory Bowel Disease-Associated Markers with Gvhd or Other Outcomes in T-Replete, Unrelated Donor Transplantation Facilitated by the NMDP

3008 Mismatch at 1-2 HLA Loci Does Not Reduce Survival Following Alemtuzumab-Based Reduced Intensity Unrelated Donor Allogeneic Transplantation

3009 Graft-Vs-Leukemia Effects of Allogeneic Stem Cell Transplantation from HLA-Haploidentical Family Members as Compared to HLA-Identical Sibling Donors

3010 Effects of Recipients' Body Weight and Total Nucleated Cell Dose on Outcomes of Unrelated Bone Marrow Transplantation: Analysis of Clinical Data of 3,114 Leukemia Patients from the Database of the Japan Marrow Donor Program

3011 TGFB1 Functional Polymorphisms: Impact on Outcome in Allogeneic Unrelated Donor Haematopoietic Stem Cell Transplantation

3012 Identifying Amino Acid Substitution Positions Associated with Day 100 Survival in Unrelated Donor Stem Cell Transplant Using Random Forest Analysis

3013 The Presence of Moderate to High Donor-Specific Anti-HLA Antibody Titers Is Associated with a High Risk of Graft Failure in Haploidentical Stem Cell Transplantation

3014 Theoretical Availability of UCBT in High Body Weight Patients Who Received Haplo-SCT for High Risk Haematological Malignancies: Results of the Simulation of Search through BMDW According to International Guidelines

3015 Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors

Biologic Therapies for NHL (Excluding Pre-clinical Models) Poster III

3048 A Phase I Study of Bortezomib in Combination with ICE (BICE) in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

3049 The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial

3050 Rituximab Plus Hypercvad Alternating with High Dose Methotrexate and Cytarabine for Patients with Newly Diagnosed Mantle Cell Lymphoma. A Multicenter Trial from GISL

3051 Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

3052 Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma

3053 A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma

3054 A Case-Control Study on the Role of  an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection

3055 Radioimmunotherapy (RIT) with 177 Lutetium-DOTA-Rituximab (177LU-D-R): A Phase I/II - Study in 30 Patients with Relapsing Follicular, Mantle Cell and Other Indolent B-Cell Lymphomas

3056 R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma

3057 Long Term Responses to Fludarabine and Rituximab in Waldenstrom's Macroglobulinemia

3058 Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

3059 Phase I/II Dose-Escalation Study of Tositumomab and Iodine I 131 Tositumomab for Relapsed/Refractory Classical or Lymphocyte-Predominant Hodgkin’s Lymphoma: Feasibility and Initial Safety

3060 R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL)

3061 90y Ibritumomab Tiuxetan as Initial Treatment for Follicular Lymphoma (ZEUS Protocol). An Italian Cooperative Study Group

3062 A Six-Month Regimen of Oral Clarithromycin Is a Feasible and Active Therapy for Patients with Relapsed/Refractory Marginal Zone B-Cell Lymphoma of MALT-Type

3063 Efficacy of 90 Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary Gastric Non Hodgkin Lymphoma

3064 Radioimmunotherapy Is Safe and Effective in Relapse after Stem Cell Transplantation for B- Cell Non Hodgkins Lymphoma, An Analysis of the International RIT-Network

3065 Incidence of Transformation to Large Cell Lymphoma and to Second Malignancies in Symptomatic Patients with Waldenstrom's Macroglobulinemia (WM) Treated with Cladribine (2-CdA) Combination Induction Therapy

3066 Evaluation of Humoral Immune Responses to Vaccination with Tetanus Toxoid and KLH in Rituximab-Treated Follicular Non-Hodgkin’s Lymphoma Patients Compared to Healthy Volunteers

Clinical Results - Allogeneic Matched Related Donor Transplantation Poster III

3291 Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial

3292 Successful Long- Term Outcome and Chimeric Status Following Allogeneic Stem Cell Transplantation for Non-Malignant Disorders Using Moderate T Cell Depletion with No Post Transplant Gvhd Prophylaxis

3293 Allogeneic Stem Cell Transplantation for Patients with Acute Leukemia Transformed from Myelofibrosis

3294 Reduced-Intensity Conditioning for Allograft (RICT) after Cytoreductive Autograft (ASCT) in Relapsed/Resistant Hodgkin’s Lymphoma (HL)

3295 Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Acute Lymphoblastic Leukemia: Better Outcome in Transplantation during First Complete Remission and with Myeloablative Conditioning

3296 HLA-Matched Sibling Stem Cell Transplantation Using Conditioning Regimen with Reduced Dose of Cyclophosphamide, ATG and Fludarabine in Patients with Severe Aplastic Anemia

3297 Addition of Umbilical Cord Blood (UCB) Unit to Reduced Intensity Conditioning (RIC) Regimen to Augment Graft Versus Tumor (GVT) in Patients (pts) with Advanced Hematologic Malignancies

3298 Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma

3299 Tandem Autologous-Nonmyeloablative (NMA) Allogeneic(Allo) Transplant (Tx) in Newly Diagnosed Multiple Myeloma (MM) Leads to Improved Survival When Compared to Conventional Allogeneic Transplant

3300 Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

3301 Cytomegalovirus Drives Acute Myeloid Leukemia Cells in Apoptosis and Reduces Thereby Markedly the Risk for Relapse after Transplant

3302 Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations

3303 Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)

3304 Low Dose Alemtuzumab Achieves Long-Term Engraftment with Low Level Mixed Chimerism in Related Haemopoietic Stem Cell Transplantation for Haemoglobinopathies

3305 Impact of Comorbidity Index on Outcome with Allogeneic Hematopoetic Stem Cell Transplantation for Chronic Lymphocytic Leukemia

3306 Outcome of Allogeneic Stem Cell Transplantation in Patients with Low Ventricular Ejection Fraction

3307 Use of Reduced Intensity Conditioning (RIC) Regimens Are Associated with a Better Outcome with Sibling Donors Transplants in Older Patients (> 50 years) with Acute Myeloid Leukemia (AML)

3308 KIR/HLA-I Mismatching Predicts Risk of Relapse in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

3309 Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloblastic Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Patients (pts) Older Than 50 Years: a Retrospective Single Center Study

3310 Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with Retained Anti-Tumor Activity

Clinical Results - Autologous Transplantation Poster III

3311 Higher Incidence of Relapse with Peripheral Blood Rather Than Marrow as a Source of Stem Cells in Adults with Acute Myelocytic Leukemia, but Not in Adults with Acute Lymphocytic Leukemia Autografted during the First Remission

3312 12 Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with Multiple Myeloma

3313 Autologous Transplantation Is the Optimum Approach to the Management of Myeloma Patients with Extramedullary Disease at Presentation

3314 Standard Consolidation /Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII / ECOG E2993)

3315 Steroid Refractoriness, but Not Rapidity of Response, to Induction Therapy Predicts for Outcome Post-Autologous Stem Cell Transplant (ASCT) in Patients (Pts) with Multiple Myeloma (MM)

3316 Melphalan 200 Mg/m2 (Mel200) Versus Melphalan 100 Mg/m2 (Mel100) in Newly Diagnosed Myeloma Patients: A Prospective, Randomized Phase III Study

3317 Double Transplantation with Melphalan (200 mg/m2) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma

3318 Autologous Stem Cell Transplantation in Patients with Autonomic Neuropathy Due to AL Amyloidosis

3319 Incorporating Marrow Plasma Cell Infiltration at Diagnosis and Cytogenetic Features into Prognostic Scoring at Point of Autologous Stem Cell Transplantation for Multiple Myeloma

3320 A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma

3321 Prognostic Value of Bone Marrow Angiogenesis in Patients with Multiple Myeloma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

3322 Lack of HLA Class I Ligands for Autologous Inhibitory KIR Is Associated with Improved Survival Following Autologous Stem Cell Transplant for Children with Neuroblastoma

3323 Evaluation of Serum Free Light Chains and Outcome in Multiple Myeloma Patients with an Intact Monoclonal Immunoglobulin Treated with Autologous Stem Cell Transplantation

3324 A High Long-Term Survival Were Produced by Early Sequential Intensive Consolidation Chemotherapy Followed by Autologous Stem Cell Transplantation in First Complete Remission in Patients with Adult Acute Lymphoblastic Leukemia

3325 Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma

3326 Total Marrow Irradiation (TMI): A New Ablative Regimen as Part of Tandem (T) Autologous Peripheral Blood Progenitor Cell Transplant (AT) for Patients (pts) with Multiple Myeloma (MM)

3327 Outcome of African-American (AA) Multiple Myeloma (MM) Patients after Autologous Stem Cell Transplantation (ASCT): A Single-Center Experience

3328 Outcome of Patients with IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplants: A Retrospective CIBMTR Study

3329 Early Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune Recovery but Improved Responses and Overall Survival

3330 Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with Bortezomib for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial

3331 Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Benefit from the Newer Drugs Used in the Relapsed Setting

3332 A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration

3333 Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) for Multiple Myeloma (MM): An Analysis from the Center for International Blood and Marrow Transplant Research (CIBMTR)

3334 Improvement of Long-Term Survival after High-Dose Melphalan in Patients with Light Chain Amyloidosis Responding to Induction Chemotherapy

3335 Superior Incidence of Progression-Free Survival (PFS) Following High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM) Patients Receiving Pre-Transplant Induction with IMiDs Versus Conventional VAD Induction Chemotherapy

Experimental Transplantation - GVHD and GVL Poster III

3499 Induction of Invariant NKT Cell-Dependent Alloreactivity by Administration of G-CSF after Bone Marrow Transplantation

3500 A Liposomal Formulation of KRN7000 (RGI-2001) Potently Reduces GvHD Lethality through the Expansion of CD4+Foxp3+ Regulatory T Cells in Murine Models

3501 Induced CD4+CD25+ FOXP-3+ and CD8+CD25+ FOXP-3+t Cells Exhibit a Concurrent Expression of Effector and Selective Suppressive Capacities  

3502 Potent Activation of Healthy Donor T-Cells Specific for Mantle Cell Lymphoma Immunoglobulin Derived Peptides by CD40- and TLR7/8-Ligand Matured Dendritic Cells in Vitro

3503 Emergence of Dominant T-Cell Populations in Patients with CLL after Allogeneic Transplantation:Mediators for Gvl Effects?

3504 HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1 Specific T Cell Responses Showing Immunogenicity of All HLA-DPB1 Alleles

3505 Cytotoxic T Lymphocytes (CTL) Specific for Adenovirus and CMV Can Be Generated from Umbilical Cord Blood for Adoptive Immunotherapy

3506 Recruitment of Donor T Cells to Secondary Lymphoid Tissue Is Enhanced by Conditioning Therapy and Donor T Cells/Marrow

3507 Lack of “Bystander” Activation and Evidence for Competition for Resources among Gvh-Reactive CD4 T Cells

3508 Host Environment Determines the Development of Gvhd but Not the Extent of Activation and Expansion of Gvh-Reactive CD4 T Cells

3509 Redundant Mechanisms for Dendritic Cell Activation in GVΗD Induction: Signalings Via TLRs, TNF-α, IL-1 and CD40 Are Not Required

3510 Soluble Lymphotoxin Plays a Critical Role in Acute Graft-Versus-Host Disease

3511 Recipient Langerhans Cells Are Neither Required Nor Sufficient for GVΗD Induction in MHC-Matched Allogeneic BMT, but a Langerin+ Cell Is a Pivotal Regulator of Langerhans Cell Turnover Post Transplantation

3512 Disruption of Gamma Interferon Signaling through the STAT1 Pathway Enhances Alloreactivity While Abrogating GvHD

3513 SOCS3 Regulates Th1 Dependent Acute Graft-Versus Host Disease

3514 Donor T Cells Lacking IFN-Gamma Receptor Expression Enhance Donor Myeloid Engraftment and Decrease Early Acute Graft-Versus-Host Disease Mortality Following Allogeneic Bone Marrow Transplantation

3515 Lentiviral Engineered T Regulatory Cells Effectively Inhibit Lymphocytes Alloreactivity across Major HLA Barriers

3516 Only MHC-Identical Donor CD4+CD25+ Regulatory T Cells Convey Full Protection from Lethal Graft-Versus-Host Disease

3517 Vß Spectratype-guided  Separation of Graft-Versus-Host Disease and Graft-Versus-Leukemia Effects in a MHC-Matched miHA-Mismatched Mouse Model of Hematopoietic Stem Cell Transplantation

3518 Cytolytically Defective Tregs Can Prevent Spontaneous Autoimmune Disease and Gvhd, but Fail to Suppress Autochthonous Lymphoproliferation

3519 A Novel Approach to Prevent GvHD: Donor Cells Engineered to Display on Their Surface a Recombinant Form of FasL Protein Effectively Prevent Lethal GvHD in a Mouse Model

3520 Use of R-spondin1, An Intestinotrophic Mitogen, in the Treatment of Murine Graft-Versus-Host Disease

3521 Flagellin, a TLR5 Agonist, Down-Regulate CD62L on Donor T Cells and Limit GvHD in Allogeneic Hematopoietic Stem Cell Transplantation

3522 Prevention of Acute GvHD during Haplo-BMT: Evaluating the Efficacy of T-Cell Costimulation Blockade Using a Novel Rhesus Macaque Transplant Model

3523 Composition and Persistence of Donor Cell Infiltrates in Host Target Organs Instigate the Development of Chronic Graft-Versus-Host Disease

Lymphoma: Chemotherapy and Clinical Trials Poster III

3586 VNCOP-B (Etoposide, Mitoxantrone, Cyclophosphamide, Vincristine, Prednisolone, Bleomycin) Plus Rituximab Therapy in Elderly Patients with Aggressive B-Cell Non-Hodgkin Lymphoma: A Phase II Study of Efficacy and Safety

3587 Liposome-Encapsulated Doxorubicin Is Highly Active in Patients with B- as Well as T/ NK-Cell Lymphomas and Cardiac Comorbidity or Older Age

3588 The Baseline PET SUV Correlates Better with Clinical Outcome Than the Post-Therapy PET Scan in Previously Untreated Patients with Histologically Aggressive Non-Hodgkin Lymphoma (NHL)

3589 Poor Outcome for Children and Adolescents with Progressive Disease or Relapse of Lymphoblastic Lymphoma - a Report of the BFM Group

3590 Gray Zone Lymphomas: Clinical and Histological Characteristics and Treatment with Dose-Adjusted-EPOCH-R

3591 Treatment of Primary CNS Lymphoma in the Elderly, a Multicenter Retrospective Analysis

3592 Treatment of High Grade B-Cell Lymphoma with Chemotherapy Plus Rituximab: A Survival Benefit Can Be Demonstrated in the Routine Data of a Regional Cancer Registry

3593 Intensified CHOP (ICHOP) +/- Rituximab in Primary Mediastinal Diffuse Large B Cell Lymphoma (PMBCL): The Role of Doxorubicin/Cyclophosphamide Dose-Intensity

3594 High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Primary CNS Lymphoma: Updated Results from a Pilot and Phase II Study

3595 Rituximab Added to CODOX-M/IVAC Is Highly Effective in HIV-Negative and hiv-Positive Burkitt Lymphoma

3596 The Addition of Systemic High-Dose Methotrexate (HD-MTX) to Intrathecal Chemotherapy (IT) for Central Nervous System (CNS) Prophylaxis Substantilly Reduces CNS Recurrence Rates in Patients with at-Risk Aggressive Lymphoma: A Historically Controlled Prospective Study

3597 High Remission Rates and Prolonged Progression Free Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma Treated with R-MACLO-IVAM-T

3598 Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313)

3599 A Phase II Study of the Combination Chemotherapy Consisted of Rituximab and THP-COP Regimen as First-Line Treatment for Patients with Diffuse Large B-Cell Lymphoma

3600 Long-Term Disease Control in Patients with Primary Central Nervous System Lymphoma

3601 Treatment Outcome and Prognostic Factors in Patients with Precursor B and T Lymphoblastic Lymphoma

3602 Relapse of Central Nervous System Lymphoma after systemic Lymphoma (SCNSL): Clinical Features and Outcome as compared to Primary CNS Lymphoma (PCNSL) Patients

3603 Treating Lymphoma with Curative Intent in HIV Positive Patients after the Advent of HAART: A Comparative Analysis with the HIV Negative Population

3604 R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2-3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18-64 Years

3605 Importance of Relative Dose Intensity for Survival in Diffuse Large B-Cell Lymphoma Patients Treated with CHOP-Like Regimen

3606 Long-Term Outcome of AIDS-Related Lymphoma Treated with Abbreviated Cycles of EPOCH-RR: A Prospective Study of 40 Patients

3607 Interim 18f[FDG] Positron Emission Tomography in Patients with Diffuse Large B-Cell Lymphoma

3608 The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study)

3609 Gem-(R)CHOP Versus (R)CHOP: A Randomized Phase II Study of Gemcitabine Combined with (R)CHOP in Untreated Aggressive Non-Hodgkin’s Lymphoma - EORTC Lymphoma Group Protocol 20021

3610 High-Dose Methotrexate and Early Intensification of Therapy Do Not Improve 3 Year EFS in Children and Adolescents with Disseminated Lymphoblastic Lymphoma.  Results of the Randomized Arms of COG A5971

3611 High-Dose Methotrexate and Cytarabine Chemotherapy May Be Effective and Safe in Solid Organ Transplant Recipients with Primary CNS Lymphomas (PCNSL)

3612 Excellent Immune Recovery Following the Intensive Chemotherapy CODOX-M/IVAC, An Effective Therapy for HIV-Associated Burkitt’s Lymphoma (BL)

3613 Reduction of Immunosuppression and Subsequent Rituximab Monotherapy or CHOP-Based Chemotherapy +/- Rituximab as a Treatment for PTLD Does No Impair the Renal Graft Function: A Matched Pair Control Analysis in 55 Renal Transplant Recipients with PTLD and 1075 Renal Transplant Controls

3614 Results of the Largest Study on Post-Transplant-Lymphoproliferations (PTLDs) of the Central Nervous System (CNS) in the Rituximab Era: A Surprising Overrepresentation of Kidney Transplantations, Key Importance of Methotrexate (Mtx), Cytarabine (AraC) and Radiotherapy (RX) for Long Term Survival and Low Impact of Rituximab (R)

3615 No Benefit from Rituximab Containing Regimens in Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma

3616 THP-COP Regimen for the Treatment of Peripheral T Cell Lymphoma and Adult T Cell Leukemia/Lymphoma: A Multicenter Phase II Study

Non-Hodgkin’s Lymphoma - Biology, Excluding Therapy Poster III

3742 PI3K/AKT-and JAK3-Dependent Regulation of SKP2 Expression Is Mediated by E2F1 in Anaplastic Large Cell Lymphoma

3743 NT-ProBNP Is the Strongest Prognostic Factor for Survival in Lymphoma Patients Following Treatment with Curative Intent

3744 Use of MicroRNA Expression Profiling to Identify Prognostic Subclasses in Mantle Cell Lymphoma: Mir-29 Family as New Prognostic Markers

3745 Mantle Cell Lymphoma International Prognostic Score Is Valid and Confirmed in Unselected Cohort of Patients Treated in Rituximab Era

3746 The Stage-Specific Effect of Interleukin-1 Beta (IL-1β) during Human Natural Killer Cell Development

3747 Neither CD68+ Nor CD163+ Macrophages Are Associated with Decreased Survival in Follicular Lymphoma

3748 Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR-1) Is Expressed in Low Grade NHL and B-CLL and Activates the Non Canonical Wnt Pathway

3749 IgA and IgG Hypogammaglobulinemia Is a Constitutive Feature in Most Waldenstrom’s Macroglobulinemia Patients and May Be Related to Mutations Associated with Common Variable Immunodeficiency Disorder (CVID)

3750 Outcomes in Subcutaneous Panniculitis-Like T-Cell Lymphoma (STCL)

3751 Role of Human Endogenous Retroviruses in Lymphoma Pathogenesis and a Possible Biomarker of Disease

3752 High-Throughput Cloning of T(11;14) Breakpoints Outside the Major Translocation Cluster in Mantle Cell Lymphoma

3753 Incidence Clinical Characteristics and Survival of Non Splenic Marginal Zone Lymphomas: A Population Based Study from a Cancer Registry in Northern Italy

3754 Lymphomas in Rheumatoid Arthritis Patients Treated with Anti-TNF Therapy: A Report from the Swedish Biologics Register (ARTIS) and the ARTIS Study Group 1998-2006

3755 Early Response Using Serum Immunoglobulin Free Light Chain (sFLC) Measurement Predicts Response  to Therapy in Waldenstrom Macroglobulinemia (WM)

3756 A Prognostic Role for Absolute Lymphocyte Counts in Pediatric Non-Hodgkin's Lymphoma

3757 Identification of Huntingtin Interacting Protein 1 Related (HIP1R) as a Novel Lymphoma Autoantigen Using Antigen Array Profiling

3758 Immune-Related and Inflammatory Conditions Likely Play a Role in the Development of Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia

3759 Sequential Chemotherapy Followed by High Dose Therapy and Autologous Stem Cell Rescue for Mantle Cell Lymphoma: Impact of MIB-1 on Outcome

3760 Regulation of p27 by S-Phase Kinase- Associated Protein 2 Is Associated with Aggressiveness in Diffuse Large B Cell Lymphoma (DLBCL)

3761 Aberrant Co-Expression of Key Transcription Factors BCL6, IRF4 and FOXP1 Are Frequently Observed in Diffuse Large B-Cell Lymphoma

3762 Genetic Variation in Genes That Regulate T-Cell Differentiation and Function Is Associated with An Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma

3763 Mirna Profiling Reveals Specific Patterns for Normal B Cell Subsets and B Cell Lymphomas with a Unique Burkitt Lymphoma Profile

3764 Marginal Zone Lymphoma: Factors That Affect the Final Outcome, a Study of 275 Patients

3765 Distinct Role of Src Family Kinase Inhibitors in Burkitt Lymphoma Cells Vs. Diffuse Large B-Cell Lymphoma Cells

3766 Epidemiological and Clinico-Pathological Features of Systemic Peripheral T-Cell Lymphomas (PTCL): A Population-Based Analysis from the Danish Lymphoma Registry LYFO

3767 Lymphoma-Expressed VEGF-a, VEGFR-1, VEGFR-2, and Microvessel Density Are Not Predictive of Overall Survival in Follicular Lymphoma

3768 Risk of Hepatitis B Virus (HBV) Reactivation and Role of Anti-Viral Prophylaxis in Lymphoma Patients with Past HBV Infection (HBV Antigen negative but anti-Hepatitis B core antibody positive) Receiving Chemo-Immunotherapy

3769 LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study

3770 Identification of Differentially Expressed Genes in the Rituximab-Resistant Clone (Ramos RR1) Compared to Wildtype Sensitive Ramos: Therapeutic Implications in Rituximab-Resistance

3771 Higher Intakes of Vegetables, Vitamin E, Manganese and Zinc Are Associated with a Lower Risk of Non-Hodgkin Lymphoma (NHL):  Results from a Case-Control Study

3772 Are Mast Cells a Biologic Predictor of Outcome in Follicular Lymphoma?

3773 Human Herpesvirus 8 Protein K1 Interferes with Fas-Mediated Apoptosis Induces Clonal Growth and Lymphoid Hyperplasia

3774 Arachidonic Acid Metabolism-Related Molecules as Candidate Markers in Subclassification of Lymphoma

3775 CD4 Cell Count of More Than 250/Microl in the Peripheral Blood Is Associated with Improved Overall Survival in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Independent of the aaIPI

3776 Networking Modules of Canonical and Alternative NFkB Signaling in Growth and Survival Regulations of Large B Cell Lymphomas

3777 Follicular Non-Hodgkin Lymphoma Grade 3a and 3b Subtypes Exhibit Similar Clinical Behaviour and Treatment Outcome

3778 CD4+Foxp3+ Regulatory T Cells Persist in High Numbers in Peripheral Blood after Induction of Clinical Remission with Standard Chemotherapy and Suppress Tumor-Specific Effector T Cells in Patients with Follicular Lymphoma

3779 High-Throughput Sequencing for Diagnosis, Prognosis and Monitoring of Lymphoid Malignancies

3780 Distinct Patterns of Systemic Immune Dysregulation in Indolent B Cell Lymphoma

3781 From Signalosome to Enhanceosome: The Translocation of CD40 from Membrane to Nucleus Involves Multiple Mechanisms

3782 Prognostic Significance of BCL6 Translocation in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP

3783 The Impact of Rituximab Resistance on Overall Survival Rate in Low-Grade Follicular Lymphoma

Autologous Transplantation: Lymphoma

769 Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma: Long Term Follow up of a Randomized Trial of the

770 High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation (auto-SCT) Versus CHOP Regimen in Patients with Untreated Aggressive Non-Hodgkin’s Lymphoma: An Update of the GOELAMS 072 Trial with a Median Follow-up of 9.8 Years

771 Survival Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative Autotransplantation (HDC) : A GELA Phase II Study

772 Autologous Stem Cell Transplantation after Myeloablative Therapy in First Remission May Be Beneficial in Patients with Advanced Stage Follicular Lymphoma after Front-Line Therapy with R-CHOP. An Analysis of Two Consecutive Studies of the German Low Grade Lymphoma Study Group (GLSG)

773 Autologous Stem Cell Transplantation (auto-SCT) as the Treatment of Choice for Follicular Lymphoma Patients in First Relapse: Final Analysis of the Outcome of  175 Patients Treated in the GELA/GOELAMS FL 2000 Study

774 Patients with Mature T-Cell Lymphoma Show High Relapse Rates after High Dose Therapy and Autologous Stem Cell Transplantation

775 Normalization of FDG-PET Pre-ASCT with Additional Non-Cross Resistant Chemotherapy Improves EFS in Patients with Relapsed and Primary Refractory Hodgkin Lymphoma-Memorial Sloan Kettering Protocol 04-047

776 Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant-Eligible Relapsed and Primary Refractory Hodgkin Lymphoma

Clinical Transplantation - Transplantation Regimen Toxicities and Engraftment 2

793 Reduced Intensity Versus Conventional Myeloablative Conditioning (RIC vs. MAC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the Acute Leukemia Working Party of EBMT

794 Second Unrelated Donor (URD) Transplant as a Rescue Strategy for 122 Patients with Primary Non Engraftment:  Results from the CIBMTR

795 Fludarabine Exposure Is Associated with Increased Treatment Related Mortality after Nonmyeloablative Hematopoietic Cell Transplantation (HCT)

796 Age-Dependent Pharmacokinetic Profile of Single Daily Dose Intravenous Busulfan in Children Undergoing Reduced-Intensity Conditioning Stem Cell Transplantation

797 Thrombotic Microangiopathy with Tacrolimus/Sirolimus-Based GVHD Prophylaxis Regimen in Patients Undergoing Hematopoietic Stem Cell Transplant from a Matched Unrelated Donor

798 Comparative Assessment of Weighting Comorbidities in the Hematopoietic Cell Transplantation (HCT) Specific Comorbidity Index (HCT-CI)

799 Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS

800 Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) Is Accompanied by Endotoxemia, Activation of Endotoxin-Directed Innate Immunity, and Deficiency of Endogenous Proteins That Limit Endotoxin-Induced TNF Production

Diffuse Large B-cell Lymphoma: Molecular Biology

801 Mutations in Multiple Genes Cause Deregulation of the NFkB Pathway in Diffuse Large B-Cell Lymphoma

802 BCL6 Regulates Tonic BCR Signaling in Diffuse Large B-Cell Lymphomas by Repressing the SYK Phosphatase, PTPROt

803 Gene Expression Profile Analysis According to Recurrent Gene Copy Number Abnormalities Defines a Diffuse Large B-Cell Lymphoma Subgroup Characterized by 9p21 Locus Deletion, Ribosome Machinery Deregulation and Poor Prognosis. A GELA Study

804 Lymphomas with Concurrent T(14;18) and 8q24 Translocations Are Under-Reported and Clinical Outcome Depends on the MYC Partner

805 Differentiation-Stage-Specific Expression of MicroRNAs in B-Lymphocytes and Diffuse Large B-Cell Lymphomas (DLBCL)

806 MicroRNA Is Prognostic Indicator in Patients with Diffuse Large B Cell Lymphoma

807 Genome-Wide Analysis of B Cell Non-Hodgkin’s Lymphoma Disclosed Frequent Involvement of Genes in NFkB Pathway

808 A Population of Suppressive Monocytes Inhibiting T Cell Proliferation and Dendritic Cell Differentiation in Relapsed Non-Hodgkin's Lymphoma

Incorporation of Rituximab into Clinical Management of NHL

832 Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

833 Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years:  Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL)

834 Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial

835 Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression

836 Rituximab Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

837 Rituximab Fails to Reduce Histologic Transformation (HT) Rate of Follicular Lymphoma (FL) to Diffuse Large B-Cell Lymphoma (DLBCL)

838 Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab + FAB Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children’s Oncology Group Report

839 The Addition of Rituximab Eliminates the Negative Prognostic Impact of PMBCL Compared to DLBCL in Young Patients with CD20-Positive Aggressive Lymphomas Receiving a CHOP-Like Chemotherapy: Results of a Subgroup Analysis of the Mabthera International Trial Group (MInT) Study

Preclinical Studies in NHL: Novel Antibodies and Immunotherapeutic Approaches

880 I-131-Anti-CD45 Radioimmunotherapy Effectively Targets and Treats T-Cell Non-Hodgkin's Lymphoma

881 An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

882 Cyclin D1 as a Universally-Expressed Mantle Cell Lymphoma-Associated Tumor Antigen for Immunotherapy

883 Novel Mechanisms of Non-Apoptotic Cell Death Evoked by Type II Anti-CD20 (Tositumomab) and HLA-DR Monoclonal Antibodies

884 Cancer Stem Cell Activity in Mantle Cell Lymphoma Is Inhibited by TLR9 Activation

885 Lenalidomide Repairs Suppressed T Cell Immunological Synapse Formation in Follicular Lymphoma

886 Combination Anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody Therapy Has in Vitro and in Vivo Activity in Mantle Cell Lymphoma

887 Co-Treatment with Panobinostat Enhances Bortezomib-Induced Unfolded Protein Response, Endoplasmic Reticulum Stress and Apoptosis of Human Mantle Cell Lymphoma Cells